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This thesis is based on a unique cohort of women with singleton pregnancies 
and intact membranes, without preterm labor or signs of infection, who under-
went mid-trimester amniocentesis for genetic testing at Sahlgenska University 
Hospital/Östra, Gothenburg, Sweden during 2008–2017. Its focus is on the 
composition of amniotic fluid as a key to gain a deeper understanding of the 
normal delivery process and the etiology of spontaneous preterm delivery. 
Fundamental concepts of pregnancy such as the placenta, fetal membranes and 
amniotic fluid are presented, as well as the delivery, with especial focus on 
preterm delivery in general and spontaneous preterm delivery in particular. The 
thesis has a particular emphasis on inflammation, as inflammatory processes 
are highly involved in pregnancy maintenance and delivery, both at term and 
at preterm. The thesis further comprises more summaries and discussions than 
descriptions in order to reflect thoughts and decisions made along the way, but 
also to minimize repetitions of the constituent papers. For the sake of clarity, 
the term “gestational age” is used when referring to the pregnancy, while 
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Background: The biological mechanisms and physiological pathways of 
pregnancy maintenance and timing of delivery are complex and multifactorial. 
Pregnancy clocks, partly controlled by timing mechanisms linked to fetal 
development, which regulate the onset of labor has previously been described. 
These clocks include inflammatory processes, involving endocrine, 
mechanical and genetic factors. However, the sequence and timing of events 
preceding the spontaneous onset of labor, both at term and at preterm, are as 
yet incompletely identified. Spontaneous preterm delivery, defined as delivery 
before 37 weeks of gestation, is a serious global health problem accounting for 
the majority of all perinatal deaths and half of the short- and long-term 
postnatal morbidity. Identifying women at risk of spontaneous preterm 
delivery is complicated by its heterogeneous etiology and several different sub-
phenotypes. Mid-trimester amniocentesis, clinically performed for prenatal 
genetic testing, provides a unique opportunity to obtain insight into the 
intrauterine environment in asymptomatic women early in gestation. However, 
the complex and dynamic composition of amniotic fluid changes continually 
as pregnancy progresses, making early identification of factors involved in the 
process of spontaneous preterm delivery and other pregnancy complications, a 
major challenge.  
Objective: The aim of this thesis and its constituent papers was to identify 
specific biomarkers related to the development of subsequent spontaneous 
preterm delivery, by examination of mid-trimester amniotic fluid composition 
in asymptomatic women. During the period of doctoral studies, new data 
emerged, indicating that a shift to gestational duration as the main outcome 
might increase the likelihood of finding associations that could assist in the 
prediction of spontaneous preterm delivery. The aim thus partly shifted toward 
investigating associations between mid-trimester amniotic fluid composition 
and gestational duration.  
Material and methods: All constituent papers in this thesis are based on 
subsets of a single cohort of 1,240 amniotic fluid samples collected from 
asymptomatic women aged over 18 years with a singleton viable pregnancy, 
intact membranes, without preterm labor or signs of infection, undergoing 
genetic amniocentesis at gestational weeks 14-19 at Sahlgrenska University 
Hospital/Östra, Gothenburg, Sweden during September 2008 to December 
2017. Demographics and clinical data were obtained from medical records at 
inclusion and after delivery. Studies investigating inflammatory, immuno-
logical and cellular-metabolic markers were designed to contribute to early 
identification of women with subsequent spontaneous preterm delivery and to 
study associations with gestational duration. Amniotic fluid samples were 
analyzed with targeted hypothesis-driven approaches using multiplex tech-
nologies such as Luminex xMAP and Meso-Scale Discovery, as well as with 
broad, untargeted hypothesis-generating approaches such as proteomics and 
metabolomics. The proteomics analyses were followed by validation/replica-
tion with Enzyme-Linked Immunosorbent Assay, a singleplex technology.  
Results: No mid-trimester amniotic fluid biomarkers associated with spontan-
eous preterm delivery were identified. Thrombospondin-1, macrophage in-
flammatory protein-1 beta and S100 calcium-binding protein A8, two alarmins 
and one chemokine, were found to be significantly associated with gestational 
duration in women with a spontaneous onset of labor at term. Gestational age 
at sampling was strongly associated with protein concentrations in several of 
the constituent studies.  
Conclusions: I) Biological signals in early mid-trimester amniotic fluid may 
be of insufficient strength for accurate risk prediction of spontaneous PTD, or 
the condition may result from acute events not detectable in amniotic fluid as 
early as at mid-trimester; II) Alarmins and chemokines, which seem to play an 
essential role in the inflammatory processes preceding the spontaneous onset 
of labor at term, can be detected in amniotic fluid as early as in the mid-
trimester; III) The concept of a pregnancy clock is strengthened by our 
findings, which also suggest that this is reflected in the amniotic fluid, where 
deviations from the clock may precede spontaneous preterm delivery; and IV) 
The results emphasize the importance of adjusting for gestational age at 
sampling when performing amniotic fluid biomarker studies. 
Keywords: amniotic fluid, biomarkers, cytokine, damage-associated 
molecular pattern, gestation, gestational duration, inflammation, labor, mid-
trimester, multiplex, pregnancy clock, proteins, spontaneous preterm delivery, 
term delivery  
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SAMMANFATTNING PÅ SVENSKA 
 
Bakgrund: De biologiska och fysiologiska mekanismer som styr graviditetens 
fortskridande och som initierar förlossningsstart är komplexa och multi-
faktoriella. Graviditetsklockor, som reglerar förlossningsstarten och delvis 
kontrolleras av tidsmekanismer kopplade till fostrets utveckling, har tidigare 
beskrivits. Dessa klockor involverar inflammatoriska processer med inslag av 
endokrina, mekaniska och genetiska faktorer. Dock saknar vi idag 
grundläggande förståelse för de händelser som föregår den spontana 
förlossningsstarten samt vid vilken tidpunkt och hur dessa uppstår, såväl vid 
förlossning i fullgången tid som i förtid. Spontan förtidsbörd, förlossning före 
graviditetsvecka 37+0, är ett allvarligt globalt folkhälsoproblem som står för 
majoriteten av all neonatal mortalitet och hälften av den neonatala 
morbiditeten, både på kort och lång sikt. Tillståndets heterogena etiologi och 
olika subfenotyper försvårar möjligheten att identifiera kvinnor som riskerar 
att föda spontant för tidigt. En amniocentes i andra trimestern, utförd i enlighet 
med kliniska rutiner för fosterdiagnostik, skapar en unik möjlighet att få 
tillgång till biologiskt material som kan ge insikt i den intrauterina miljön hos 
asymtomatiska kvinnor i tidig graviditet. Fostervattnets komplexa och 
dynamiska sammansättning förändras dock i takt med att graviditeten 
fortskrider. Att tidigt identifiera faktorer som är involverade i utvecklingen av 
spontan förtidsbörd och andra graviditetskomplikationer är därför en stor 
utmaning. 
Syfte: Syftet med denna avhandling och dess ingående delarbeten var att 
identifiera specifika biomarkörer relaterade till spontan förtidsbörd genom att 
studera sammansättningen av fostervattnet från asymtomatiska kvinnor i andra 
trimestern. Under projektets gång har nya forskningsresultat publicerats som 
indikerar att möjligheten att finna associationer som kan bidraga till att 
prediktera spontan förtidsbörd ökar om fokus istället läggs på att studera 
graviditetslängd som huvudsakligt utfall. Vårt fokus skiftades således delvis 
under tidens gång till att även studera associationer mellan fostervattnets 
sammansättning och graviditetslängd. 
Material och metoder: Samtliga ingående delarbeten i denna avhandling är 
baserade på subgrupper ur en enda kohort bestående av 1240 fostervatten-
prover från asymtomatiska kvinnor ≥18 år med en viabel singelgraviditet som 
genomgick fosterdiagnostisk amniocentes i graviditetsvecka 14-19 vid 
Sahlgrenska Universitetssjukhuset/Östra, Göteborg, Sverige, under september 
2008 till december 2017. Demografiska och kliniska data har samlats in från 
medicinska journaler vid inklusion och efter förlossning. Studier som 
undersökte inflammatoriska och immunologiska markörer samt cellulär 
metabolism i fostervattnet utformades för att, i ett tidigt skede, kunna 
identifiera kvinnor som riskerarde att drabbas av spontan förtidsbörd samt för 
att bidraga med ny kunskap kring de processer som reglerar graviditetslängd. 
Fostervattenproverna analyserades med riktade hypotesdrivna 
multiplexmetoder såsom Luminex xMAP och Meso-Scale teknologi, samt 
med breda hypotesgenererande metoder såsom proteomik och metabolomik. 
Proteomikanalyserna följdes av validering/replikering med singleplex-
analyser (enzymkopplad immunadsorberande analys).  
Resultat: Vi fann inga biomarkörer i fostervattenprover från tidig andra 
trimester som var associerade med spontan förtidsbörd. Trombospondin-1, 
makrofaginflammatoriskt protein-1 beta och S100 kalciumbindande protein 
A8, två alarminer och en kemokin, visade sig vara  signifikant associerade med 
tidpunkt för spontan förlossningsstart i fullgången tid. Gestationsålder vid 
provtagning var starkt associerad med proteinkoncentrationer i flera av de 
ingående delarbetena.  
Slutsatser: I) Biologiska signaler i fostervatten från andra trimestern kan vara 
av otillräcklig styrka för att kunna förutsäga spontan förtidsbörd, eller så 
uppstår spontan förtidsbörd som en följd av akuta händelser som kanske inte 
kan upptäckas i fostervatten så tidigt som i andra trimestern; II) Alarminer och 
kemokiner, vilka verkar ha en väsentlig funktion i de inflammatoriska 
processer som föregår en spontan förlossningsstart i fullgången tid, kan 
identifieras redan i andra trimestern; III) Konceptet om en graviditetsklocka 
styrks av våra resultat, och de antyder att denna även reflekteras i fostervatten, 
där avvikelser från klockan skulle kunna föregå en spontan förtidsbörd; och 
IV) Resultaten av de ingående delarbetena betonar vikten av att justera för 
gestationsålder vid provtagning i studier där fostervatten analyseras i syfte att 
finna biomarkörer.  
Nyckelord: fostervatten, biomarkörer, cytokin, damage-associated molecular 
patterns, graviditet, graviditetslängd, inflammation, förlossning, andra 
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1 Abbreviations  
1.1 General abbreviations 
 
AF  Amniotic fluid 
BMI  Body mass index 
°C   Degrees Celsius 
CRL  Crown-rump length 
CP  Cerebral palsy 
HCA  Histological chorioamnionitis 
IAI  Intra-amniotic inflammation 
IVF  In vitro fertilization 
LMP  Last menstrual period 
MIAC  Microbial invasion of the amniotic cavity 
NIPT  Non-invasive prenatal testing 
PPROM  Preterm prelabor rupture of membranes  
PTD  Preterm delivery 
PTL  Preterm labor 
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1.2 Abbreviations related to analyses 
 
ANCOVA  Analysis of covariance 
ELISA  Enzyme-linked immunosorbent assay 
g  Gravity (relative centrifugal force) 
IQR Interquartile range 
LC-MS/MS Liquid chromatography-tandem mass spectro-
metry 
MAP  Multi-analyte profiling 
pg/mL  Picogram per milliliter  
pH  Potential hydrogen 
QF-PCR Quantitative fluorescent-polymerase chain 
reaction 










1.3 Abbreviations related to inflammatory markers  
 
CRP  C-reactive protein 
GM-CSF Granulocyte-macrophage colony stimulating 
factor 
DAMP Damage-associated molecular pattern 
HMG1 High-mobility group protein 1 
HSP70 Heat-shock protein 70 
IFN  Interferon 
IGFBP   Insulin-like growth factor-binding protein 
IL  Interleukin 
MIF  Macrophage migration inhibitory factor 
MIP  C-C motif chemokine [macrophage inflamma-
tory protein] 
MMP   Matrix metalloproteinase 
NT  Neurotrophin 
S100A8  S100 calcium-binding protein A8 
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2.1 General introduction 
 
Preterm delivery (PTD), defined as delivery occurring before 37 weeks of 
gestation, is the largest problem in current obstetric and neonatal care (1, 2) 
and a serious global health problem (3). Complications of PTD include severe 
short- and long-term morbidity (4) and it is the leading cause of neonatal death 
and of death in children aged under five (5). The prediction of PTD is 
complicated by its multifactorial and complex heterogeneous etiology, 
including several different sub-phenotypes (6). The two major ones are 
spontaneous and iatrogenic (medically indicated delivery due to maternal or 
fetal conditions) PTD (3), of which the former constitutes the focus of this 
thesis.  
The process of spontaneous PTD is hypothesized to be initiated early in 
gestation (7). During the last decades, tremendous progress has taken place in 
neonatal and pediatric care, improving survival and decreasing the severity and 
frequency of morbidity in preterm-born infants (8). The rate has, however, 
been relatively stable in Sweden during the last 45 years (9). Few obstetric 
advances have resulted from the plethora of studies analyzing proteins, bacteria 
and metabolites in maternal blood, vaginal and cervical fluid and amniotic 
fluid. This research project therefore studied hitherto asymptomatic women in 
order to detect underlying processes in their early stages, with the aim of 
enabling identification of potential prognostic or diagnostic biomarkers before 
onset of symptoms. Improved understanding of the pathways leading to 
spontaneous PTD could lead to new insights in the spontaneous PTD etiology 
which eventually reduce the rate and related fatal consequences.  
Amniotic fluid is the biological compartment with the highest likelihood of 
mirroring the dynamic intrauterine biological environment. This thesis 
therefore focus on mid-trimester amniotic fluid samples, obtained in 
conjunction with a clinically indicated ultrasound-guided transabdominal 
amniocentesis. The procedure is somewhat controversial since it aims at 
diagnosing fetal chromosomal abnormalities and is associated with an 
increased risk of miscarriage. However, recent studies suggest that the increase 
is as low as 0.06% to 0.13% (10-12). Due to the rapidly developing diagnostic 
landscape, amniocentesis rates have decreased significantly, indicating that 
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Efforts in spontaneous PTD research have aimed at identifying a reliable and 
solid biomarker (13). However, early prediction of spontaneous PTD will most 
likely not be based on a single marker, but rather on coordinated networks (14). 
The papers employed hypothesis-driven or hypothesis-generating strategies to 
contribute to understanding of causal factors triggering the onset of labor. As 
yet, no biomarker has been identified that accurately predict spontaneous PTD, 
neither of asymptomatic women in the mid-trimester nor of symptomatic 
women in the late second or third trimesters. It is apparently challenging to 
predict spontaneous PTD early in gestation but even more challenging to affect 
the process later in gestation once symptoms have occurred. It is therefore 
crucial to identify new strategies to address this difficult situation.  
The biological mechanisms and physiological pathways of pregnancy 
maintenance and the timing of delivery include inflammatory, immunological, 
endocrine, mechanical and genetic factors and processes, but the sequence and 
timing of events preceding the spontaneous onset of labor, both at term and at 
preterm, are as yet incompletely identified. During the last years, several 
studies have reported on different pregnancy clocks, partly controlled by 
timing mechanisms, which regulate the onset of labor by synchronizing to the 
fetal development (15-19). During the course of the research underlying this 
thesis, it was suggested that treating a variable such as gestational age as a 
continuous variable, using its full interval, instead of as a dichotomous trait 
(term/preterm) would increase the statistical power in identifying associations 
that could also assist in the prediction of spontaneous PTD (20). This is 
supported by genetic studies by our group in which we have identified several 
genes associated with gestational duration at term, a few of which are also 
related to spontaneous PTD (21). Data indicated that the phenotype of 
pregnancy maintenance and timing of delivery become more homogeneous as 
pregnancy progresses, causing stronger biological associations at term than at 
preterm. Our focus thereby expanded to also investigate associations between 
mid-trimester amniotic fluid composition and gestational duration. We hoped 
that this strategy would improve the chance of detecting associations that could 
contribute to the prediction of spontaneous PTD. As decreasing gestational 
duration within both the term and preterm intervals increases the risk of 








The first stage of embryonic development consists of fertilization, preceded by 
a two-week pre-embryonic development of the conceptus. The embryo 
devolves, by definition, into a fetus by the ninth gestational week (23). The 
fetus contains both maternal and paternal genetic material and the paternal 
genes are foreign to the pregnant woman. Under other circumstances, the 
immune system would attack and eliminate this foreign body (24). However, 
during gestation, signals and responses originating from the maternal immune 
system, in combination with the fetal-placental immune system, result in 
different immunological phases (25) that together prevent immune-mediated 
rejection (24, 26).  
Pregnancy is characterized by three distinct immunological phases, also 
referred to as the three trimesters. Each trimesters is represented by different 
biological processes (24, 27) in pro-inflammatory or anti-inflammatory 
environments (28, 29). The pregnancy itself also elicits a general inflammatory 
response, with significantly increased serum concentrations of C-reactive 
protein (CRP), total white blood cells (WBC), neutrophils, granulocyte-
macrophage colony stimulating factor (GM-CSF) and lactoferrin in all 
trimesters (30). 
Inflammation is a key physiological process in pregnancy and delivery (31). 
The first trimester of pregnancy consists of a pro-inflammatory phase (24, 32) 
that extends into the early second trimester. Following implantation and 
placentation, a strong inflammatory response is necessary to adequately repair 
the uterine epithelium and remove cellular debris (33, 34). The second 
trimester of pregnancy, also referred to as the mid-trimester, entails rapid fetal 
growth and development and an anti-inflammatory state, in which the pregnant 
woman, placenta and fetus are in symbiosis (35, 36). The immune system must, 
however, still protect the pregnant woman and fetus from external harmful 
pathogens. This occurs through substantial expression of anti-inflammatory 
mediators and reduced expression of many cytokines linked to host defense 
and inflammatory immune capacity (26). During the third trimester, fetal 
development is completed and all organs are functional. A pro-inflammatory 
phase recurs (35, 36) in preparation for delivery, leading to a cascade of events 
that trigger myometrial contractions and cervical remodeling.   
Cytokines, low-molecular-weight proteins and small intercellular signal 
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cells (38-41). They are found in varying concentrations in amniotic fluid and 
in fetal and maternal serum before and during labor (42-46). Cytokines are 
capable of modulating the behavior of other cells (37) and affecting 
prostaglandin production (47-50). One cytokine can have different effects, 
depending on its concentration and its interaction with other cytokines and the 
type of target cell (37).  
 
2.2.1 The placenta 
 
Early in gestation, the placenta is shaped from embryonic (trophoblastic) and 
maternal (endometrial) tissues (23). It has unique features, essential for the 
developing fetus. It is an important tissue barrier, thick in early gestation to 
protect the fetus from external influences. As the pregnancy progresses and the 
placenta develops, this barrier attenuates by the second month of gestation (51)  
in order to facilitate diffusion of nutrients and oxygen from maternal to fetal 
blood. It also serves as a carrier that removes embryonic metabolic waste from 
fetal to maternal blood (23). Toxins, such as environmental pollutants, drugs, 
alcohol, and tobacco (23, 51), may nonetheless enter fetal blood by crossing 
the placental barriers. This may cause fetal physiological abnormalities or 
congenital malformations (23). The placenta is thus not impenetrable, but does 
serve as a natural barrier. Studies suggest that size, material composition and 
surface characteristics such as solubility are crucial factors determining 
whether it is permeated by particles (52-55). 
 
2.2.2 The fetal membranes 
 
During the first weeks of gestation, the embryonic membranes, including the 
internal amnion, yolk sac, allantois and external chorion, are formed. The 
amnion fills with amniotic fluid and eventually extends all the way around the 
embryo (23) and lines the uterine cavity (19). The yolk sac produces the earliest 
blood cells and later forms part of the gut. The allantois constitutes the 
structural base of the umbilical cord, which contains a core of embryonic 
connective tissue, the umbilical arteries and the vein. Externally, it is covered 
by the amniotic membrane which links the fetus to the placenta. The allantois 
also becomes part of the fetal urinary bladder. Finally, the chorion, involved in 
 
 
placentation, constitutes the outermost membrane enclosing the embryo and 
all the other membranes (23). The much thicker trophoblast layer is directly 
linked to the maternal decidua and consists of trophoblasts procured from the 
yolk sac and allantois. (19). It forms the chorionic villi that grow on contact 
with maternal blood. They later form the umbilical arteries and the vein, all 
protected by the outer layer, the decidua (23).  
 
2.2.3 Amniotic fluid 
 
The amnion, with its content of amniotic fluid, provides a buoyant environment 
that cushions and protects the developing embryo from physical trauma (23, 
56). It also assists in the maintenance of a constant homeostatic temperature, 
prevents the rapidly growing embryonic parts from adhering (23), reduces the 
risk of compression between the uterine wall and the fetus (57) and supports 
fetal growth (56) by allowing the embryo considerable freedom of movement, 
enabling musculoskeletal development (23, 58) and development and growth 
of the gastrointestinal and pulmonary systems. The amniotic fluid also has 
antibacterial properties that protect the fetus from infectious agents (58). 
During the first 20 weeks of gestation, amniotic fluid is similar to fetal plasma. 
It is mainly derived from maternal plasma (23, 56), water and solutes that pass 
through the fetal membranes or across the placenta. It also consists of organic 
macromolecules (carbohydrates, proteins, lipids) and hormones (58). The 
amniotic fluid volume increases significantly in the second trimester, from a 
total of about 10-25 mL at gestational week 10 to a total of about 400 mL at 
gestational week 20. Although the fetal kidneys start to produce urine already 
at gestational week 8, followed shortly after by fetal swallowing, neither fetal 
urine nor swallowing contribute significantly to the content or volume of 
amniotic fluid until around gestational week 16, when the fetal kidneys are 
fully functioning (56, 58, 59). Keratinization of fetal skin usually begins at 19-
20 gestational weeks and is completed at gestational week 25. Around 
gestational week 24-28, the amniotic fluid volume reaches its peak of 
approximately 800 mL (56, 58). At this stage, the amniotic fluid is mainly 
derived from the kidneys’ excretion of fetal urine, pulmonary excretion of lung 
fluid (23, 56, 60), fetal breathing and fetal secretion of oral, nasal and tracheal 
fluid (56). Little change then occurs until near term when the amniotic fluid 
volume begins to decrease (61). The fetal skin and surfaces of the amnion, 
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a rapid bi-directional diffusion between the fetus and the amniotic fluid, in 
which the removal of amniotic fluid is predominately accomplished by fetal 
swallowing (56) and intramembranous absorption (60). 
The amniotic fluid’s complex and dynamic contents, evolving as pregnancy 
progresses and including nutrients, growth factors (56), enzymes, fetal 
epithelial cells (62), proteins (58, 61), electrolytes, immunoglobulins and 
vitamins from the pregnant woman (58), make it a highly interesting matrix for 
research. The amniotic fluid content and status reflect the current intrauterine 
environment (63). Researchers and clinicians thus use it to monitor the 
progression of pregnancy and as a source of biomarkers for the prediction of 
adverse pregnancy outcomes, such as spontaneous PTD (64-67), and adverse 
neonatal outcomes (68). 
 
2.3 Gestational age estimations  
 
For centuries, Naegele’s rule has been used to estimate pregnancy duration. 
This is based on a 28-day ovulatory cycle with ovulation on cycle day 14. The 
estimated date of delivery is calculated in four steps: 
1. Determine the first day of the last menstrual period (LMP) 
2. Add seven days 
3. Count back three calendar months 
4. Add one year 
Naegele’s rule is still used in developing countries, whereas ultrasound 
measurement has taken over gestational age estimation in the industrialized 
world. As each woman has her individual menstrual cycle, ultrasound 
measurement is considered to be more accurate (69) and has remained the most 
reliable method for gestational age estimation (70) since its introduction in 
obstetrics over 50 years ago. It is a safe procedure when used appropriately 
(71), but it should only be performed when clinically indicated. Scan duration 
should be limited, as data indicate that the energy used to obtain ultrasound 
images may have an effect on tissues (72) and the fetus. 
Gestational age estimation is important for several reasons; it is the basis for 
the timing of prenatal visits, examinations, screening tests and certain 
interventions, it is essential for accurate assessment of certain laboratory 
 
 
results and it is vital when delivery is medically indicated or when elective 
cesarean section is planned (70). Gestational age estimation is initially based 
on the LMP, except for pregnancies conceived by in vitro fertilization (IVF), 
for which it is based on the date of embryo transfer. The golden rule is that the 
best clinical estimate of gestational age should always serve as the basis for 
dating the pregnancy. Table 1 presents an overview of the most accurate 
method for gestational age determination based on the number of days that the 
ultrasound-determined date differs from the date according to the LMP.   
Table 1. The most accurate method for gestational age estimation. Data from 
the Committee on Obstetric Practice, the American Institute of Ultrasound in 




(days) Most reliable method 
   
< 9+0 ≤ 5 LMP > 5 Ultrasound examination 
   
≥ 9+0 – ≤ 13+6 ≤ 7 LMP > 7 Ultrasound examination 
   
≥ 14+0 – ≤ 15+6 ≤ 7 LMP > 7 Ultrasound examination 
   
≥ 16+0 – ≤ 21+6 ≤ 10 LMP > 10 Ultrasound examination 
   
≥ 22+0 – ≤ 27+6 ≤ 14 LMP > 14 Ultrasound examination 
   
 
It is recommended that all pregnant women undergo a transvaginal or 
abdominal ultrasound scan before 22+0 gestational weeks to confirm or revise 
the estimated LMP-based gestational age (70). Pregnancies for which this 
recommendation has not been followed are considered to be suboptimally 
dated (73). The most reliable estimate is obtained in the first trimester, at 
<13+6 gestational weeks, yielding an accuracy of ± 5-7 days (70). This is 
preferably performed transvaginally at <8+0 gestational weeks and 
abdominally at ≥ 8+0 gestational weeks (72). This early dating is based on 
crown-rump length (CRL) (74), preferably an average of three measurements. 
However, accuracy decreases when CRL >84 mm, equivalent to approximately 
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2.3 Gestational age estimations  
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2. Add seven days 
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results and it is vital when delivery is medically indicated or when elective 
cesarean section is planned (70). Gestational age estimation is initially based 
on the LMP, except for pregnancies conceived by in vitro fertilization (IVF), 
for which it is based on the date of embryo transfer. The golden rule is that the 
best clinical estimate of gestational age should always serve as the basis for 
dating the pregnancy. Table 1 presents an overview of the most accurate 
method for gestational age determination based on the number of days that the 
ultrasound-determined date differs from the date according to the LMP.   
Table 1. The most accurate method for gestational age estimation. Data from 
the Committee on Obstetric Practice, the American Institute of Ultrasound in 




(days) Most reliable method 
   
< 9+0 ≤ 5 LMP > 5 Ultrasound examination 
   
≥ 9+0 – ≤ 13+6 ≤ 7 LMP > 7 Ultrasound examination 
   
≥ 14+0 – ≤ 15+6 ≤ 7 LMP > 7 Ultrasound examination 
   
≥ 16+0 – ≤ 21+6 ≤ 10 LMP > 10 Ultrasound examination 
   
≥ 22+0 – ≤ 27+6 ≤ 14 LMP > 14 Ultrasound examination 
   
 
It is recommended that all pregnant women undergo a transvaginal or 
abdominal ultrasound scan before 22+0 gestational weeks to confirm or revise 
the estimated LMP-based gestational age (70). Pregnancies for which this 
recommendation has not been followed are considered to be suboptimally 
dated (73). The most reliable estimate is obtained in the first trimester, at 
<13+6 gestational weeks, yielding an accuracy of ± 5-7 days (70). This is 
preferably performed transvaginally at <8+0 gestational weeks and 
abdominally at ≥ 8+0 gestational weeks (72). This early dating is based on 
crown-rump length (CRL) (74), preferably an average of three measurements. 
However, accuracy decreases when CRL >84 mm, equivalent to approximately 





biparietal diameter, head circumference, abdominal circumference and femur 
length, is recommended for estimating gestational age (70). This is optimally 
performed at around gestational weeks 18-20. A full fetal anatomic survey can 
be performed at this time as well (71). However, this second-trimester 
ultrasound does not provide the basis for gestational age estimation if the 
estimated date of delivery is established at a first-trimester ultrasound (70).  
There is controversy regarding the accuracy of ultrasound dating between 
gestational weeks 14+0 and 27+6. However, it is generally agreed that 
accuracy improves with decreasing gestational age within this interval (71). 
The most inaccurate period for gestational age determination is thus the third 
trimester, during which the margin of error is up to ± 21-30 days (70).  
  
2.4 Delivery  
 
2.4.1 Timing of delivery 
 
Timing of delivery is biologically regulated (6, 75), and the onset of labor 
results from coordinated signals, as well as from maternal and fetal endocrine 
and immune events (35, 76-81). Pregnancies that last for 259-293 days, 
corresponding to 37+0 to 41+6 gestational weeks (and days), are considered to 
be at term (82, 83). This is quite a broad interval, but the term pregnancy group 
has previously been considered to be rather homogeneous, and has constituted 
the basis for comparison of risks associated with preterm and post-term 
deliveries (82). However, data increasingly suggest that there is a significant 
difference in the outcomes of infants delivered in the term pregnancy interval. 
The group has thus been divided into sub-groups based on gestational duration 
within the term interval (Table 2). Infants born at early term post-term are 
suggested to have an increase in neonatal morbidity, compared with those born 
at full and later term (82, 83). Infants born at full term have the lowest rate of 





Table 2. Subgroups of gestational duration at term. Modified from Fleischman 
et al. (82) and Spong et al. (83) 
Definition Gestational duration (weeks+days) 
  
Early term 37+0 – 38+6 
  
Full term 39+0 – 40+6 
  
Late term 41+0 – 41+6 
  
Post-term ≥ 42+0 
  
 
Fetal maturity and growth are thus a continuous process. At a certain stage at 
term, the fetus has reached a size equivalent to that of the entire delivery 
channel. This is referred to as the “obstetric dilemma”, a key mechanism from 
an evolutionary point of view, for the well-being and survival of the fetus and 
its mother (75). At this stage, the fetus has also reached a certain level of 
development and is physiologically prepared to maintain homeostasis as a 
neonate. The conditions for neonatal survival are thus optimal (19).  
 
2.4.2 The delivery process 
 
At the time of delivery, coordinated signals trigger an inflammatory process 
(35, 36, 84) in several gestational tissues such as the cervix, decidua, fetal 
membranes and myometrium (19). This creates a pro-inflammatory 
environment that transforms the myometrium from a quiescent to a highly 
contractile state (19, 85) with strong, rhythmic muscle contractions (19). It 
results in edema, neutrophil infiltration and expression of pro-inflammatory 
cytokines and chemokines (86-88). Several cascade pathways are involved in 
this process, such as the endocrine and immune systems and prostaglandins 
(37). Estrogens also play an important role, reaching peak concentrations in 
maternal blood during the last weeks of gestation, causing the uterus to 
contract. Oxytocin, produced by the fetus, causes the placenta to release 
prostaglandins and the two powerful uterine muscle stimulants cause more 
regular contractions. The hypothalamus is activated and more oxytocin is 
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throughout gestation and changes into a lubricant just before labor, also assists 
in the process (23). Altogether, this leads to increased uterine activity, cervical 
remodeling and weakening of the fetal membranes, which facilitates the 
rupture of the chorioamniotic membranes (85, 89). This process is referred to 
as the common pathway of parturition (19).  
Despite partial knowledge of the common pathway of parturition, the exact 
sequence and synchronization of the coordinated events preceding the 
spontaneous onset of labor and controlling gestational duration have not as yet 
been fully characterized, either from a biological or mechanistic standpoint. It 
has though recently been suggested that each of these local and systemic 
signals or events constitutes an intrinsic functional clock or alarm with 
interdependent timing mechanisms. Such a biological clock can function as a 
device that records events or as a responder monitoring the level and number 
of specific signals or events (e.g. nutrient availability or concentration of 
circulating hormones) (19). Corticosteroid hormones are powerful synchroniz-
ers of such biological clocks, and they have long been thought to control the 
timing of delivery. In most mammalian species, increased corticosteroid 
concentrations are evident in the maternal and fetal circulations and amniotic 
fluid prior to the onset of labor (90). 
The wide variability in human gestational duration at term, the incidence of 
early and post-term deliveries and the associated neonatal risks ultimately 
suggest the existence of multiple, redundant clock and monitoring systems. 
These may be controlled by the extent to which any individual clock dominates 
over other physiological or pathophysiological signaling mechanisms that stem 
from infection or metabolic derangement. Such biological pregnancy clocks 
could count recurring events and/or monitor a threshold of specific signals. 
Clock-like mechanisms, coordinating fetal maturation with delivery, have been 
described in sheep and mice. The issue of whether similar systems control the 
gestational duration of human pregnancies is currently the object of intense 
research (19). 
It has further been hypothesized that the uterus is sensitive to several 
inflammatory developmental factors such as fetal membrane senescence, as 
well as to environmental factors such as social stress or infections, and that 
labor is triggered when an inflammatory load threshold is surpassed. Uterine 
wall distention is likely involved in a similar feedback mechanism. Senescence 
(19), the natural and physiological aging processes (91, 92) of the fetal 
membranes (amnion and chorion) (19), has also been hypothesized as a key 
contributing factor to the onset of labor (91, 92). It constitutes a counting 
device, modified by different factors including oxidative stress. Damage-
 
 
associated molecular patterns (DAMPs), endogenous mediators, reflect 
changes in fetal membrane physiology (19). They are released from fetal mem-
branes or by an inflammation in the choriodecidual space (93), transmitted to 
the decidual layer via leukocyte and natural killer cell activation (94), where 
they cause immune activation (95), tissue damage (19) and trigger an 
inflammatory process (96, 97), known as senescence-associated inflammation 
(94), constituting sterile inflammation (91, 92). This is associated with an 
overall increase of the fetal membranes’ inflammatory load that change the 
quiescent myometrium to an active state (94), leading to the onset of labor (98). 
Several DAMPs have been reported in laboring tissue, including high-mobility 
group box (HMG) 1, heat-shock protein 70 (HSP70), uric acid, single- and 
double-stranded DNA and RNA, S100 calcium-binding protein A8 (S100-A8) 
and hyaluronan (81, 93, 99-103). Theses hypotheses that have arisen during 
the last couple of years, indicating that the intrauterine environment may not 
be as sterile as previously thought, are though hotly debated (104-106).  
 
2.5 Preterm delivery 
 
2.5.1 Definitions and consequences  
 
The upper limit of PTD is globally agreed (3, 107), while the lower gestational 
age limit for PTD varies in the world. In Sweden, it is set at 22 gestational 
weeks, while it is 20 gestational weeks in the United States and Australia (6). 
Despite the low rate of PTD in Sweden (9, 108), it accounts for over 70% of 
all perinatal deaths and half of all short- and long-term postnatal morbidity 
(109-111), such as chronic lung, vision, hearing and neurological problems. 
About 7-8% of children born at <28 weeks of gestation will develop cerebral 
palsy (CP). CP is a major international health problem and the most common 
physical disability in childhood (112-114). More than 50% of children with CP 
also have other associated neurological conditions, such as mental retardation 
or epilepsy (115-117).  
The single strongest risk factor for severe neonatal morbidity is the degree of 
immaturity at birth (118). The respective number of neonatal deaths worldwide 
is equal among deliveries at <28+0 gestational weeks, at 28+0 to 31+6 
gestational weeks and at 32+0 to 35+6 gestational weeks. This is because there 
is a higher rate of PTD in the later gestational intervals, while the individual 
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indicate an increasing survival rate, even at the earlier gestational weeks (119). 
Table 3 presents the survival rate of liveborn children in Sweden during 2013-
2017.  
Table 3. Approximate survival rate of preterm-born neonates in Sweden, 
2013-2017. Data from Läkartidningen (6) 
Gestational duration 
(weeks+days) Survival rate (%) 
  
22+0 – 22+6 53 
  




28+0 – 31+6 97 
  
32+0 – 36+6 99 
  
   
2.5.2 Epidemiology  
 
There are several socio-demographic or lifestyle risk factors associated with 
PTD, among which are ethnicity, low socioeconomic or educational status, 
inadequate prenatal care, single marital status, maternal age <18 or >40 years, 
smoking, alcohol and drug abuse, hard working conditions, anxiety and 
depression, low or high maternal body mass index (BMI) (3, 120, 121), 
maternal short stature, maternal stress and domestic violence (6). There are 
also obstetric risk factors, such as previous PTD or previous second-trimester 
pregnancy loss, multiple pregnancy, an inter-pregnancy interval of <6 months, 
low maternal gestational weight gain, vaginal bleeding, infection/ 
inflammation, oligo- or polyhydramnios, abdominal surgery in the second or 
third trimester, cervical procedures during gestation, uterine anomalies (3, 120, 
121), myoma, assisted fertilization, altered vaginal flora, male fetal gender and 
primiparity. Recent studies also suggest that 25-30% of all PTD have a genetic 
association and the first data on genes related to PTD and gestational duration 
have recently been published (21). However, in more than 50% of all cases of 
PTD cases, known or obvious risk factors are missing (122). 
Spontaneous PTD originates from multiple causes such as infection, 
inflammation, vascular disease and uterine overdistension (3). The most 
 
 
important risk factors for spontaneous PTD are previous PTD, which increases 
the risk two- to sixfold (6), and short cervix in the second trimester (23). Other 
risk factors include black race, periodontal disease and low maternal BMI (3).  
 
2.5.3 Rates  
 
There are large geographical variations in PTD rates, both nationally (123) and 
internationally (124), and only a minor part of these geographical differences 
can be explained by known risk factors (6). In Sweden, the PTD rate, currently 
5.7%, has been relatively stable during the last 45 years (9, 108).  
Approximately 2% occur at <34+0 gestational weeks and 0.3% occur at <28+0 
gestational weeks (9). Denmark and Norway have slightly higher rates, 
approximately 6.0-6.5% (108, 124). These Nordic rates are low, compared to 
reported rates of up to 20% in some parts of the world (Fig.1). The highest 
rates are reported in India, China, Nigeria, Bangladesh and Indonesia, and 
these five countries together account for approximately 44.6% of all PTDs 
globally (125). A general worldwide increase in PTD has been observed over 
the last 30-40 years, especially in the developing countries, most likely due to 
the increase in iatrogenic PTDs and the increased number of twin pregnancies 
after IVF (6).  
Figure 1. Global estimated rates of PTD in 2014, published in Chawanpai-
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PTD is divided into subgroups based on gestational duration (Table 4). The 
majority (approximately 60%) of all PTDs are late or near-term PTD. The rate 
thereafter decreases by decreasing gestational duration; moderately PTD 
accounts for 20% of all PTDs while severely and extremely PTD accounts for 
15 % and 5%, respectively (3).  
Table 4. Subgroups of PTD. Data from Goldenberg et al (3) and Fleischman 
et al. (82) 
Definition Gestational duration (weeks+days) 
  
Extremely PTD <28+0 
  
Severely PTD 28+0 – 31+6 
  
Moderately PTD 32+0 – 33+6 
  
Late or near-term PTD 34+0 – 36+6 
  
 
PTD is also divided into subgroups according to origin; multiple pregnancies, 
malformations and intrauterine fetal deaths, spontaneous and iatrogenic (3). 




Figure 2. Subgroups of preterm delivery. Data from Morken et al (9). 
Illustration by Jan Funke.   
2.6 Spontaneous preterm delivery  
 
Spontaneous PTD accounts for 75% of all PTDs and constitutes preterm labor 
(PTL), defined as regular uterine contractions and cervical ripening, and 
preterm pre-labor rupture of membranes (PPROM), defined as spontaneous 
rupture of the fetal membranes with leakage of amniotic fluid at least one hour 
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2.6 Spontaneous preterm delivery  
 
Spontaneous PTD accounts for 75% of all PTDs and constitutes preterm labor 
(PTL), defined as regular uterine contractions and cervical ripening, and 
preterm pre-labor rupture of membranes (PPROM), defined as spontaneous 
rupture of the fetal membranes with leakage of amniotic fluid at least one hour 
prior to the onset of regular uterine contractions (3) (Fig.3).  
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Figure 3.  Subgroups of spontaneous preterm delivery. Data from Golden-
berg et al (3)
 
and Morken et al (9). Illustration by Jan Funke.
 
 
2.6.1 Etiology  
 
Despite decades of research, the multifactorial and complex etiology of 
spontaneous PTD is incomplete, as is understanding of the sequence and 
timing of events preceding the condition (9, 84, 126-133). The exact mecha-
nisms that trigger the inflammatory process (35, 89, 134) have not been 
completely identified but there are some important common pathophysio-
logical processes in spontaneous PTD etiology: maternal stress, maternal 
systemic or genital tract infections, placental ischemia or vascular lesions, 
cervical disease and uterine overdistension (135-137). Mechanical distention 
of the fetal membranes, that induce inflammatory cytokine expression, tissue-
level inflammation (138, 139) and fetal membrane senescence, are also 
associated with spontaneous PTD, the latter especially in cases of PPROM (19) 
(Fig.4). The processes have different initiators and factors that vary somewhat 
according to gestational duration within the PTD interval (135).  
 
 
Figure 4. Common pathways in onset of spontaneous PTD. Data from 
Menon et al. (19), Behrman et al. (135), Goncalves et al. (136), Romero et 
al. (137), Hua et al. (138) and Kendal-Wright (139), modified from 
Läkartidningen (7).
 
Illustration by Jan Funke.
  
 
In many cases, spontaneous PTD occur as a result of a foreign stimulus, 
originating from foreign bodies or bacterial pathogens which causes an 
infection that triggers an inflammatory response in maternal and fetal tissues. 
These infectious and subsequent inflammatory processes (9, 84, 126-132) are 
particularly present in cases of extremely PTD. There are several ways for 
bacteria to reach the amniotic cavity. Among the most common are ascension 
from the lower genital tract, crossing the cervical barrier and invasion of the 
decidua, chorioamniotic membranes and amniotic cavity (84). This is defined 
as microbial invasion of the amniotic cavity (MIAC) (96, 97). Studies suggest 
that up to 20-60% of women with PTL at <28 weeks of gestation and 10-25% 
of women with PTL at 28-32 weeks of gestation have MIAC, verified by 
positive culture for related microorganisms (140-142). The pathogenesis of 
PTL is, however, not yet completely understood and it may also occur as an 
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membranes, which usually act as a barrier, are ruptured. In these cases, MIAC 
can cause spontaneous labor within a couple of days after membrane rupture, 
but a minority with PPROM remain undelivered for weeks or months (143). 
The subsequent intra-amniotic inflammation (IAI) causes an increased release 
of several amniotic fluid inflammatory markers, such as interleukin-6 (IL-6) 
(142, 144-150), other pro-inflammatory cytokines and chemokines (131, 146, 
148, 149, 151), tumor necrosis factor alpha (140, 146, 148, 152), or matrix 
metallo-proteinase-8 (MMP-8) (153-155), as well as a release of 
prostaglandins (156, 157). This trigger myometrial contractions, membrane 
rupture and cervical maturation (84, 156-159), leading to spontaneous PTD 
(84, 156-159). Women with PTL may, however, have IAI if the amniotic fluid 
culture is negative, referred to as sterile IAI (93).  
MIAC and IAI are separated into four subgroups based on the presence or 
absence of infection or inflammation (96, 97): sterile IAI (IAI is present, MIAC 
is absent), MIAC-associated IAI (both MIAC and IAI are present), MIAC 
alone (IAI is absent) and a negative subgroup without MIAC or IAI (Fig.5). 
However, it has been hypothesized that IAI is not just simply present or absent 
but rather a continuum, where clinical outcomes are correlated with gradations 
of the inflammatory response based on the number of biomarkers present in 
amniotic fluid (160).  
Figure 5. Subgroups of MIAC and IAI. Data from Romero et al (93), 
Combs et al. (96) and Cobo et al. (161). Illustration by Jan Funke. 
 
 
Microbiological and histological evidence, and clinical signs of MIAC and/or 
IAI in the mother may not always coincide. Histological chorioamnionitis 
 
 
(HCA) is defined as infection of the uterine cavity, fetal membranes and 
placenta. However, DAMPs or alarmins cause HCA to the same extent as 
bacteria (162). The prevalence is inversely correlated with gestational duration, 
and studies suggest that HCA is present in as many as 50% of all cases of 
spontaneous PTD (163). The later spontaneous PTD occurs in gestation, the 
more likely that the HCA is of non-infectious origin (6).  
The IAI resulting from MIAC is measurable in the choriodecidual and 
chorioamniotic spaces, amniotic fluid, umbilical cord, fetus and, rarely, the 
placenta (159), as shown in Fig.6. Other pathways have, however, been 
discussed, such as via maternal blood or the oral buccal mucosa (6). Both 
MIAC and IAI are associated with short latency to delivery (131, 140, 142, 
145, 147, 150-155, 164) and high rates of perinatal morbidity and mortality 
(140, 142, 150, 152, 154, 164, 165), especially in infants that showed signs of 
inflammation already in fetal life.  
Figure 6. Sites of intrauterine inflammation and infection. Modified from 
Goldenberg et al. (159) and Läkartidningen (6). Illustration by Jan Funke. 
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2.6.2 Biomarkers  
 
Biomarkers are measurable biological markers or indicators of normal or 
pathological processes (166). Since the majority of women with spontaneous 
PTD lack known risk factors (167) and since the condition is most likely quite 
advanced once symptoms occur, there is an urgent need to study asymptomatic 
women for the early detection of prognostic or diagnostic biomarkers that can 
predict risk. Asymptomatic women identified early in gestation are also those 
most likely to benefit most from preventive interventions.  
The ideal biomarker for spontaneous PTD would be easily tested early in 
gestation and would identify both high and low risk women with a low false 
positive rate. However, due to limited understanding of mechanisms involved 
in spontaneous PTD etiology, time of onset and duration of the asymptomatic 
state, the identification of reliable biomarkers is a major challenge. As both 
IAI and MIAC are strongly associated with spontaneous PTD (168), amniotic 
fluid is an interesting biological matrix for biomarker discovery (169). 
Attention has primarily been devoted to biomarkers (170, 171) involved in 
inflammatory pathways associated with spontaneous PTD (172). However, 
systematic reviews of symptomatic women in the third trimester or shortly 
prior to delivery, examining a wide range of potential biomarkers, conclude 
that none of these are clinically useful for the prediction of spontaneous PTD 
(171, 173).  
A meta-analysis and systematic review of the literature concerning women in 
the first or mid-trimester suggest an association between elevated concentra-
tions of  IL-6 and MMP-8 and decreased concentrations of glucose in amniotic 
fluid, and spontaneous PTD (169). Hus et al. also suggest mid-trimester 
amniotic fluid concentrations of IL-6 as a potential biomarker for spontaneous 
PTD prediction (174). However, the results of these two studies are 
inconsistent with others. No single first or mid-trimester biomarker has neither 
as yet emerged that can predict which women will delivery spontaneously 
preterm (175). 
In summary, several systematic reviews of both targeted and untargeted 
approaches at all gestational ages have reached an unanimous conclusion; 
multiple and intricate pathways are involved in spontaneous PTD etiology and 
it is therefore unlikely that one single biomarker would serve as a reliable 
predictor (171, 176-179). Diverse study designs and sampling procedures, as 
 
 
well as the adoption of different analytical approaches in diverse technological 
assay platforms, contribute to heterogeneity and variability of results (180). 
  
2.6.3 Prediction strategies 
 
There are a few strategies for the diagnosis of symptomatic women with 
threatening PTD, especially in cases of PPROM, which is still unpredictable 
and unpreventable. Prevention is challenged by the fact that the most common 
symptoms (contractions, back pain, menstruation-like pain, increased vaginal 
discharge) are frequent during normal pregnancy as well. Effective prediction 
methods are therefore needed for this group of women. In Sweden, clinical 
assessment includes evaluation of the pain and frequency of contractions and 
cervical status (length, consistency and dilation), but there are also several 
commercially available biochemical tests, the most common of which is the 
quantitative fetal fibronectin test. Low concentrations of fetal fibronectin 
indicate low risk of PTD with a good negative predictive value, while high 
concentrations indicate increased risk of PTD, but with a limited positive 
predictive value (181). Studies suggest the benefit of combining fetal 
fibronectin with cervical length measurement (182), but the former is as yet in 
limited clinical  use in Sweden. Tests with high negative predictive value will 
reduce unnecessary interventions and hospitalization of women with 
threatening PTD (7), decreasing societal costs. To further improve prediction, 
biomarkers or predictive tests can be used in combination with epidemiological 
risk factors (183).  
Measuring cervical length by transvaginal ultrasound at gestational weeks 18-
23 is one of the most applied methods globally for predicting spontaneous PTD 
in asymptomatic women. There are, however, several confounders related to 
cervical structure and development that may bias results. Furthermore, many 
studies include a high proportion of high-risk women, limiting generalizability. 
There appears to be clinical value in repeated measurement within a couple of 
days after the first measurement, as this may indicate progression (7). 
However, there is little evidence that cervical length measurement predicts 
spontaneous PTD within 7 days in asymptomatic or symptomatic women. On 
the other hand, it may be useful in clinical management by facilitating 
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2.6.4 Preventive strategies and treatments of 
asymptomatic women  
 
A few preventive strategies and treatments are available, such as progesterone, 
cervical cerclage and cervical pessary, and it is more or less recommended for 
different risk groups. Progesterone, produced by the placenta from the second 
or third month of gestation (23), is secreted into the maternal circulation in 
large amounts (19). It prepares and maintains the endometrium and is a key 
factor in suppressing the maternal immunologic response to fetal antigens. 
Maternal rejection of the trophoblast is thereby prevented, a requirement for 
pregnancy maintenance (184). Progesterone also plays an important role in 
maintaining uterine and decidual quiescence, inhibiting myometrial contrac-
tility and sustaining cervical closure (185, 186). Administration of pro-
gesterone as a preventive strategy has been widely and hotly debated for 
several years. Current evidence does not support the administration of pro-
gesterone, either as intramuscular 17-hydroxiprogesterone or vaginal micro-
nized progesterone, to asymptomatic women with a prior history of PTD (187-
189). In asymptomatic women with a short cervix (≤25 mm) in the late mid-
trimester, vaginal micronized progesterone reduces PTD at <34+0 gestational 
weeks, although there is no impact on long-term neonatal outcome (190). 
Cervical cerclage requires a surgical procedure but the side effects are mild 
(vaginal irritation and discharge) (7). Cervical cerclage has been postulated to 
decrease the risk of perinatal mortality and morbidity (191) and is currently 
indicated for (192, 193): 
1. women with a history of an indicated cerclage for one of the following: 
a) three or more prior early PTDs; b) trachelectomy; c) two or more 
prior early PTDs  
2. women with a prior history of PTD and cervical length ≤25 mm  
 
3. physical exam indicates cerclage, i.e. cervical dilation with visible 
amniotic membranes at < 24 gestational weeks 
 
Cervical pessary has also been proposed as a preventive strategy in 
asymptomatic women with a short cervix as it relieves pressure on the internal 
os by changing the angle of the cervix. However, study results are 




2.6.5 Treatments of symptomatic women 
 
Many interventions, aimed at prolonging pregnancy and improving the 
outcome in children born preterm, have been applied in women with PTL and 
PPROM. However, there have been few successes, especially in regard to 
improved neonatal outcome. In women with PTL and PPROM, the process 
may already be so advanced so that delivery is inevitable. Each case should be 
individually assessed, as delivery should not be prevented if the intrauterine 
environment proves harmful to the fetus (196).  
 
Treatment provided in the acute phase may be beneficial for improving the 
perinatal outcome but it may be harmful for the fetus both in the short and long 
term if delivery does not actually occur preterm (196, 197). Access to good 
prediction models and preventive strategies for women at high risk, and 
increased knowledge about effective interventions and treatments in the acute 
phase of threatening PTD, are therefore of major importance (7). 
 
Antenatal corticosteroids are administered on two occasions, with a 24-hour 
interval, at gestational weeks 23+0 to 33+6 to women with threatening PTD 
who are expected to deliver within a few days. This treatment increases the 
perinatal survival rate and reduces the risk of respiratory disorders, 
enterocolitis and intraventricular hemorrhage. A positive effect on both 
neonatal mortality and morbidity has been observed even when the interval 
between administration and delivery is short (198). The long-term outcome in 
children after antenatal corticosteroid therapy is, however, not known and there 
is a debate on the risks versus benefits of an additional single dose if more than 
two weeks have passed since the double dose was given and the woman is still 
undelivered (199).  
Tocolysis is a traditional treatment for women with threatening PTD. It blocks 
the oxytocin receptors in uterine muscle, leading to reduced tone and 
contractility (7). It has not been shown to improve neonatal outcome (200); its 
major function is rather to allow adequate treatment with antenatal 
corticosteroids for fetal lung maturity. There is no evidence that long-term 
repeated tocolytic treatment after the completion of corticosteroid therapy has 
any effect (7).  
Antenatal magnesium sulfate (MgSO4) treatment is recommended in most parts 
of the world for women with imminent PTD at <32+0 gestational weeks. 
Metaanalyses have shown that this treatment reduces the risk of neonatal brain 
injury, cerebral hemorrhage and CP (201). Further studies are however needed 
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Swedish study is ongoing, which has led to a national controlled introduction 
of MgSO4 to all women expected to delivery <32+0 gestational weeks. 
There is an association between vaginal infection or colonization with certain 
bacteria, e.g. bacterial vaginosis, and spontaneous PTD (202). Metaanalyses 
concerning screening for and treating bacterial vaginosis with antibiotics have, 
however, not shown a decreased incidence of PTD (203). Some studies on 
antibiotic treatment for threatening PTD have even suggested that it could be 
harmful for the fetus in women with PTL (204-207). In the ORACLE trial, an 
increased risk of CP was observed in children aged seven whose mothers had 
been given prenatal antibiotics for PTL (204). Some improvements in short-
term outcome, but not at the age of seven years, were found in children born 
to women with PPROM without contractions who had received prenatal 
antibiotics (205, 207). Antibiotics treatment in women with PPROM and 
clinical chorioamnionitis is routine, however, as it has not proven harmful to 
the child (7).  
Finally, studies have suggested acetylsalicylic acid as a potential treatment. It 
reduced the risk of spontaneous PTD in one study but further research is 
needed (208). 
 




Mid-trimester genetic amniocentesis is an invasive prenatal procedure, in 
which amniotic fluid is obtained from the amniotic cavity and used for fetal 
genetic diagnosis (10). The clinical procedure was introduced in the late 1960s 
(209).  
 
2.7.2 Indications for mid-trimester genetic amniocentesis 
 
Advanced maternal age is associated with an increased risk of chromosomal 
abnormalities (210-212) and is the most common indication for mid-trimester 
genetic amniocentesis (213). The number of Swedish women giving birth to 
their first child at ≥35 years of age has increased significantly during the last 
decades. In 1973, 1.7% of primiparas and 8.5% of multiparas were aged >35 
 
 
years, compared to 12.4% and 28.5%, respectively, in 2015 (214). Other 
common indications for mid-trimester amniocentesis, related to elevated risk 
of fetal chromosomal abnormalities, are a) high risk on a first- trimester 
combined screening test; b) a previous pregnancy or child with chromosomal 
abnormality; c) family history of chromosomal abnormality or genetic disease; 
and d) ultrasound finding consistent with fetal malformations. Finally, a few 
women undergo mid-trimester genetic amniocentesis due to severe anxiety.  
 
2.7.3 Risks associated with mid-trimester amniocentesis 
 
Amniocentesis performed before 14+0 gestational weeks has been reported to 
be associated with an increased risk of fetal loss (215-217), leakage of amniotic 
fluid (215, 217) and talipes equinovarus (clubfoot) in the infant (215). It is 
therefore not recommended to perform an amniocentesis before gestational 
week 15+0 (218). The reported overall risk of procedure-related fetal loss is 
inconsistent. Some studies report up to a 1.0% risk (219-221), while more 
recently reported risks are only 0.06% to 0.13% (10-12). This decrease may 
possibly be associated with the development of the technique or simply a 
question of the definition of fetal loss. Several studies report rates of fetal loss 
at <28+0 gestational weeks (11), while more recent studies have evaluated fetal 
loss at <24+0 gestational weeks (12, 222). Other studies have a cut-off at four 
weeks post-procedure (223, 224). One study reported that mid-trimester 
amniocentesis increases the risk of PTD (225), but this association has not been 
found by others (222, 226). It has, however, been suggested that some 
procedure-related miscarriages might be caused by preexisting subclinical IAI 
(63, 227-229). The same applies for second- and third-trimester hemorrhage 
following genetic amniocentesis; an old study found an association between 
amniocentesis and placental abruption (230), which was not supported by more 
recent data (231). Moreover, a possible association between early 
amniocentesis and hypertensive disorders of pregnancy has been suggested 
(232), but this was not confirmed in a more recent study (233). Finally, a few 
case reports (234-236) suggest that mid-trimester amniocentesis could be 
followed by clinical chorioamnionitis, defined as maternal temperature 
>37.8°C and >2 of the following criteria: uterine tenderness, malodorous 
vaginal discharge, fetal tachycardia (>160 beats/min), maternal tachycardia 
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Mid-trimester genetic amniocentesis is an invasive prenatal procedure, in 
which amniotic fluid is obtained from the amniotic cavity and used for fetal 
genetic diagnosis (10). The clinical procedure was introduced in the late 1960s 
(209).  
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years, compared to 12.4% and 28.5%, respectively, in 2015 (214). Other 
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amniocentesis and hypertensive disorders of pregnancy has been suggested 
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2.7.4 Amniocentesis - other applications 
 
The amniotic fluid composition mirrors changes occurring in the uterus, and 
the protein composition of amniotic fluid obtained at amniocentesis can 
therefore also reveal other causes of adverse pregnancy outcomes (63). Mid-
trimester amniocentesis thus enables the examination of the intrauterine 
environment in asymptomatic women. 
Furthermore, amniocentesis can be performed, and repeated, throughout the 
entire pregnancy. After mid-trimester, the indications are evaluation of fetal 
lung maturity in women with PTL or PPROM (238), diagnosis of MIAC or 
IAI (239), and intrauterine growth restriction (240).  
 
 
2.7.5 The diagnostic landscape 
 
The number of amniocenteses performed in Sweden has decreased during the 
last decade, from 4,541 in 2005 to 2,340 in 2014 (241). This reduction is 
mainly a consequence of developments in prenatal testing and diagnostic 
techniques, as well as of the risks related to mid-trimester amniocentesis.  
The first-trimester combined screening test (10) combines maternal age and 
nuchal translucency (ultrasound measurement of the fluid-filled area under the 
skin behind the fetal neck) (242) and maternal plasma biomarkers (protein A 
(PAPP-A) and free beta human chorionic gonadotropin (free β-hCG)) to 
estimates likelihoods of trisomy 21, 18 and 13 (243), of which trisomy 21 is 
the most common (244). Women with results indicating high risk are offered 
a genetic amniocentesis. The first-trimester combined screening test has a 90% 
detection rate for trisomy 21, with a false positive rate of 5% (245), resulting 
in a group of women who still need invasive testing if they choose to ascertain 
the fetal karyotype.  
Another non-invasive method for prenatal testing that further reduced the 
demand for invasive procedures was introduced in 2011. This method is based 
on the presence of cell-free fetal DNA in maternal plasma and is known as 
non-invasive prenatal testing (NIPT). NIPT has higher sensitivity and 
specificity and lower false positive rates, compared to the first-trimester 
combined screening test (246). This applies particularly to trisomy 21, for 
 
 
which the sensitivity is over 99%, with a false positive rate of less than 0.1% 
(247). NIPT thus minimizes the demand for invasive procedures (Table 5). 
However, despite recent advances in prenatal screening techniques, NIPT is 
though not yet a diagnostic procedure.  
 
Table 5. Detection rate of Trisomy 21 and rate of women requirering invasive 
test (equal to screen positive rate) based on different screening methods. Data 
from Nicolaides et al. (245) and Gil et al. (247). 




   
Maternal age ≥35 years 30 5 – 20 
   
Maternal age ≥35 years and second trimester  
biochemical screening 
50 – 70 5 
   
First-trimester combined screening test 90 5 
   
First-trimester combined screening test and 
ultrasound examination of the fetal nasal bone, 
heart and ductus venosus 
>95 3 
   
Cell-free fetal DNA >99.9 <0.1 
   
 
The introduction of the first-trimester combined screening test has thus 
resulted in fewer invasive tests. However, the most substantial difference 
emerged in 2017 when NIPT was introduced in clinical practice at our 
department at Sahlgrenska University Hospital/Östra. This resulted in a 
significant decrease in the number of amniocenteses, as well as in fewer 
children being born with genetic anomalies. Table 6 presents the decrease at 
our department during the study. Obviously, it was urgent to perform this study 
when we did, since these samples will not be available for research in the future 








2.7.4 Amniocentesis - other applications 
 
The amniotic fluid composition mirrors changes occurring in the uterus, and 
the protein composition of amniotic fluid obtained at amniocentesis can 
therefore also reveal other causes of adverse pregnancy outcomes (63). Mid-
trimester amniocentesis thus enables the examination of the intrauterine 
environment in asymptomatic women. 
Furthermore, amniocentesis can be performed, and repeated, throughout the 
entire pregnancy. After mid-trimester, the indications are evaluation of fetal 
lung maturity in women with PTL or PPROM (238), diagnosis of MIAC or 
IAI (239), and intrauterine growth restriction (240).  
 
 
2.7.5 The diagnostic landscape 
 
The number of amniocenteses performed in Sweden has decreased during the 
last decade, from 4,541 in 2005 to 2,340 in 2014 (241). This reduction is 
mainly a consequence of developments in prenatal testing and diagnostic 
techniques, as well as of the risks related to mid-trimester amniocentesis.  
The first-trimester combined screening test (10) combines maternal age and 
nuchal translucency (ultrasound measurement of the fluid-filled area under the 
skin behind the fetal neck) (242) and maternal plasma biomarkers (protein A 
(PAPP-A) and free beta human chorionic gonadotropin (free β-hCG)) to 
estimates likelihoods of trisomy 21, 18 and 13 (243), of which trisomy 21 is 
the most common (244). Women with results indicating high risk are offered 
a genetic amniocentesis. The first-trimester combined screening test has a 90% 
detection rate for trisomy 21, with a false positive rate of 5% (245), resulting 
in a group of women who still need invasive testing if they choose to ascertain 
the fetal karyotype.  
Another non-invasive method for prenatal testing that further reduced the 
demand for invasive procedures was introduced in 2011. This method is based 
on the presence of cell-free fetal DNA in maternal plasma and is known as 
non-invasive prenatal testing (NIPT). NIPT has higher sensitivity and 
specificity and lower false positive rates, compared to the first-trimester 
combined screening test (246). This applies particularly to trisomy 21, for 
 
 
which the sensitivity is over 99%, with a false positive rate of less than 0.1% 
(247). NIPT thus minimizes the demand for invasive procedures (Table 5). 
However, despite recent advances in prenatal screening techniques, NIPT is 
though not yet a diagnostic procedure.  
 
Table 5. Detection rate of Trisomy 21 and rate of women requirering invasive 
test (equal to screen positive rate) based on different screening methods. Data 
from Nicolaides et al. (245) and Gil et al. (247). 




   
Maternal age ≥35 years 30 5 – 20 
   
Maternal age ≥35 years and second trimester  
biochemical screening 
50 – 70 5 
   
First-trimester combined screening test 90 5 
   
First-trimester combined screening test and 
ultrasound examination of the fetal nasal bone, 
heart and ductus venosus 
>95 3 
   
Cell-free fetal DNA >99.9 <0.1 
   
 
The introduction of the first-trimester combined screening test has thus 
resulted in fewer invasive tests. However, the most substantial difference 
emerged in 2017 when NIPT was introduced in clinical practice at our 
department at Sahlgrenska University Hospital/Östra. This resulted in a 
significant decrease in the number of amniocenteses, as well as in fewer 
children being born with genetic anomalies. Table 6 presents the decrease at 
our department during the study. Obviously, it was urgent to perform this study 
when we did, since these samples will not be available for research in the future 








Table 6. Number of amniocenteses performed at Sahlgrenska University 
Hospital/Östra during the study period 















































The long-term overall aim with this project is to identify early biomarkers, gain 
insight into underlying mechanisms and to generate hypotheses that can lead 
to studies of new preventive strategies, interventions and treatments for 
asymptomatic women at early gestations with a subsequent spontaneous PTD. 
Another long-term aim was to contribute to the identification of strong 
biomarkers or networks of biomarkers detectable in more easily accessible 
biological compartments than amniotic fluid.  
The initial aim of the research presented in this thesis was to identify specific 
biomarkers related to spontaneous PTD, before the onset of clinical symptoms, 
and to provide insight into the biological mechanisms underlying the condition 
by investigating the composition of amniotic fluid from asymptomatic women 
undergoing mid-trimester amniocentesis for genetic testing. This aim is 
reflected in the case-cohort study design and the focus on spontaneous PTD 
(cases) versus term delivery (controls) as a dichotomous trait. Together with 
systems biology approaches, high-capacity techniques using DNA, RNA, 
proteins and metabolites may be the key to increased understanding of 
spontaneous PTD and to obtain a complete picture of the process. Well-
designed proteomic studies (172) and multiplex technology have shown 
promise when it comes to detecting novel predictive biomarkers (248). To 
fulfil the aim, the constituent papers of this thesis are thus based on advanced 
omics and multiplex techniques in meticulously designed studies.  
During the last couple of years, new data from our group and others have 
emerged (20, 21), indicating that analyzing gestational duration, instead of 
comparing spontaneous PTD and term delivery, might increase the likelihood 
of finding associations contributing to the prediction of spontaneous PTD. Our 
focus was thereby expanded to include investigating associations between mid-
trimester amniotic fluid and gestational duration, aiming at greater under-
standing of the inflammatory and other pathways leading to the spontaneous 
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4 Material and methods 
 
4.1 Study design 
 
The constituent papers in this thesis are all based on subsets of a single cohort 
of women who underwent mid-trimester genetic amniocentesis at Sahlgrenska 
University Hospital/Östra. The first participant was enrolled in September 
2008 and, due to the rapidly developing technology that have led to fewer 
invasive tests, the last subject was enrolled in December 2017. During that 
decade, a total of 1,223 women were recruited. The amniocentesis was 
performed on clinical indication, as described in Section 2.5.2. Women were 
followed up through their prenatal and obstetric medical records that were 
retrieved from other medical facilities if necessary. Newborns were followed 
up until age 28 days. Data concerning maternal characteristics, pregnancy, 
delivery, neonatal outcome and sampling were recorded in a comprehensive 
database created specifically for this study with the software FileMaker Pro 
(Filemaker Inc., California, USA). Sub-groups of women with spontaneous 
PTD, iatrogenic PTD, other adverse pregnancy outcomes and term deliveries 
were analyzed separately or compared to one another (Papers I-III and V), as 
well as analyzed as a cohort (Paper IV). Amniotic fluid samples were divided 
into aliquots and coupled with clinical data and outcome variables (Fig.7).  
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4.2 Inclusion and exclusion criteria 
 
Women aged over 18 with singleton pregnancies and intact membranes, 
without PTL or signs of infection and who could understand the Swedish oral 
and written information were invited to participate. Women were considered 
ineligible if they were under 18 years of age; had a multiple pregnancy; tested 
positive for human immune deficiency virus (HIV), hepatitis B or other 
infectious diseases; had severe mental illness or retardation; carried fetuses 
with known or suspected malformations; or if samples could not be collected 
due to logistic problems. Exclusion criteria were declined participation; 
language barriers; insufficient sample at amniocentesis (a few cases) and 
enrollment deemed inappropriate for medical or psychological reasons. 
 
4.3 Enrollment strategy 
 
Women were referred to mid-trimester genetic amniocentesis by their prenatal 
midwives, based on the clinical criteria described in section 2.7.2. They 
received information about their scheduled appointments, the procedure and 
this research study by mail prior to their visit. They thus had the opportunity 
to read the study information at home and to decide whether to participate. On 
arrival at the department, women (and their partners) were seen by a research 
staff member. They were given oral information about the study and the 
opportunity to ask questions. The enrollment strategy evolved over the years 
including an information screen and a leaflet rack about ongoing research. 




4.4 Ethical considerations  
 
Mid-trimester amniotic fluid offers major potential for detection of 
pathological conditions early in pregnancy in asymptomatic women. 
Participants in this study are, however, a highly selected population due to their 
advanced maternal age, homogenous ethnicity and high risk of chromosomal 
abnormalities. However, due to the risks, albeit limited, to mid-trimester 
amniocentesis, samples could only be collected in conjunction with clinically 
indicated procedures. Mid-trimester amniocentesis performed exclusively for 
research purposes would not have been ethically justifiable since research 
results do not benefit the participants.  
Amniotic fluid is produced continuously. Collection of such a small additional 
amount as 3 mL did not extend sampling duration or increase the risk of 
procedure-related complications. Study results did not affect clinical 
management since a) the analyses were performed after the women were 
delivered; b) no individual results were reported back to either participants or 
healthcare staff; and c) data are presented and published on the group level. All 
clinical data are stored in a password-protected database and kept apart from 
names and personal identification numbers, which are stored under a separate 
code key. Source documents are stored in a secure filing cabinet to which 
access  is limited to members of the research group. All material (biological 
specimens and protocols) was encoded after sampling using consecutive serial 
numbers so that a single individual could not be identified during the analytical 
phases. Data and amniotic fluid samples were thereafter connected via these 
individual serial numbers. Only the study investigators have access to the 
identification list.  
The study was approved by the Regional Ethical Board at the University of 
Gothenburg, Sweden, initially as early as in 2003. It was, however, not initiated 
until 2008, after renewed ethical approval. A short description of the ethical 
approvals are found at the end of this section. Participation was voluntary 
and women were given the same care regardless of their decision to participate. 
Written consent to participate was given just prior to the amniocentesis, and 
both the physician and the woman signed the consent form. Participants were 
informed that they could discontinue their participation, request that their 
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Permit number Dnr. Ö 639-03 was the first ethical approval for the project 
covering enrollment, sampling, some analyses, biobanking of samples and 
collection of clinical data through medical records and the Swedish National 
Board of Health and Welfare’s Medical Birth Register.  
Permit number T 318-08 derived from a requirement to obtain renewed ethical 
approval to initiate the project, as a new law had been passed since the first 
approval. We simultaneously applied to update the written information and to 
modify the title of the project.  
Permit number T 694-11 gave us permission to relate protein findings to a 
broad spectrum of pregnancy and delivery outcome variables rather than just 
spontaneous PTD. 
Permit number 2019-06022 allowed us to perform a broader variety of 
laboratory analyses on the biobanked samples, such as oxidative stress, 
bacteria, metabolites, lipids and carbohydrates.  
 
4.5 Characteristics of the cohort 
 
In total, 3176 women underwent genetic mid-trimester amniocentesis during 
the study period, of which 24.2% (770/3176) were ineligible. Approximately 
51.5% (1240/2406) of the eligible women were enrolled, while the remaining 
48.5% (1166/2406) were excluded. Of the 1240 women enrolled, 22 women 
were excluded retrospectively due to being incorrectly enrolled; suspected fetal 
malformations (n=10), infectious diseases (n=5), initial twin gestation (n=4), 
processing deviation (n=2) and identity issues (n=1), and 40 women had 
missing data on gestational duration due to missed abortion (n=3), termination 
of pregnancy (n=27), lost to follow-up (n=7) and had incomplete data (n=3). 
Of the remaining 1178 women, 93.5% (1102/1178) delivered at term while 
6.5% (76/1178) of the women had a PTD. As expected, this is slightly higher 
than the national PTD rate. The rate of spontaneous PTD was 4.3% (51/1178), 
of which 49.0% (25/51) had PTL and 51.0% (26/51) had PPROM. The rate of 
iatrogenic PTD was 2.1% (25/1178), of which 48% (12/25) had preeclampsia. 












Figure 8. Flowchart of the cohort 
 
 
Maternal and neonatal characteristics of the study cohort (n=1218), from 
which women with an intrauterine fetal death (n=7) and women with 
“other” outcomes, as shown in Fig.8 (n=40), have been excluded, are 
presented in Table 7 (n=1171). This table also presents the maternal and 
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Table 7. Maternal and neonatal characteristics of the cohort and the subgroup 
of women with a spontaneous preterm delivery. Continuous variables are 
presented as the median (interquartile range; IQR) while categorical variables 
are presented as n (%) 
Variable Study cohort  (n=1171) 
Spontaneous PTD 
(n=51) 
   
Maternal age at sampling 
(years) 
37 (34 – 39) 37 (35 – 39) 
   
Parity 
    0 
    1 
    2 











   
Maternal BMI at first 
prenatal visit 
23.5 (21.5 – 26.1) 24.9 (22.6 – 27.0) 
   
Smoking at first prenatal 
visit 
59 (5.0%) 5 (9.8%) 
   
IVF 38 (3.2%) 6 (11.8%) 
   
Previous preterm delivery 90 (7.7%) 8 (15.7%) 
   
Gestational age at 
sampling (weeks+days) 
15+5 (15+2 – 16+1) 15+5 (15+1 – 16+1) 
   
Gestational duration 
(weeks+days) 
39+5 (38+5 – 40+6) 35+6 (33+5 – 36+4) 
   
Neonatal sex 
    Male 







   
Apgar score <7 at 5 min 11 (0.9%) 1 (2.0%) 




Gestational duration of the cohort according to previously described sub-group
classifications in setion 2.5.4 and 2.4.1, respectively, are presented in Table 8 
(spontaneous PTD) and Table 9 (term delivery). The rate of extremely, 
severely and moderately PTD is slightly below the average while the group of 
women with a late or near-term PTD is more than 10 percentage points above 
average. As expected, the majority of women delivering at term were at full 
term.  
Table 8. Subgroups of PTD (n=76) with the rate presented being within the 
PTD interval. The overall rate represents the distribution of the study cohort 
(n=1178) 
Definition Rate; n (%) Overall rate (%)
Extremely PTD 3 (3.9) 0.3
Severely PTD 9 (11.8) 0.8
Moderately PTD 10 ( 13.2) 0.9
Late or near-term PTD 54 (71.1) 4.6
Table 9. Subgroups of term deliveries in the study cohort (n=1178) with the 
rate presented being within the term interval. The overall rate represents the 
distribution of the study cohort
Definition Rate; n (%) Overall rate (%)
Early term 288 (26.1) 24.4
Full term 557 (50.5) 47.3
Late term 187 (17.0) 15.9
Post-term 70 (6.4) 5.9
Fig.9 presents the indication for the amniocenteses in the whole cohort
(n=1218). As expected, the most common indication was advanced maternal 







Table 7. Maternal and neonatal characteristics of the cohort and the subgroup 
of women with a spontaneous preterm delivery. Continuous variables are 
presented as the median (interquartile range; IQR) while categorical variables 
are presented as n (%) 
Variable Study cohort  (n=1171) 
Spontaneous PTD 
(n=51) 
   
Maternal age at sampling 
(years) 
37 (34 – 39) 37 (35 – 39) 
   
Parity 
    0 
    1 
    2 











   
Maternal BMI at first 
prenatal visit 
23.5 (21.5 – 26.1) 24.9 (22.6 – 27.0) 
   
Smoking at first prenatal 
visit 
59 (5.0%) 5 (9.8%) 
   
IVF 38 (3.2%) 6 (11.8%) 
   
Previous preterm delivery 90 (7.7%) 8 (15.7%) 
   
Gestational age at 
sampling (weeks+days) 
15+5 (15+2 – 16+1) 15+5 (15+1 – 16+1) 
   
Gestational duration 
(weeks+days) 
39+5 (38+5 – 40+6) 35+6 (33+5 – 36+4) 
   
Neonatal sex 
    Male 







   
Apgar score <7 at 5 min 11 (0.9%) 1 (2.0%) 
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Fig.9 presents the indication for the amniocenteses in the whole cohort
(n=1218). As expected, the most common indication was advanced maternal 
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Figure 9. Indication for amniocenteses in the study cohort (n=1218).
4.6 Selection of study participants
The five papers constituting this thesis were performed during different years,
and all of them were performed before the whole cohort was collected. As a 
standard, we included all women with spontaneous PTD on whom we had 
complete follow-up data at the time of when the respective study was 
performed. The number of women with a spontaneous PTD in each of the 
papers thus varies and reflects the number of women who had delivered by the 
time of analysis. 
Initially, we used a nested case-cohort design, to focus on spontaneous PTD 
versus term delivery, in Papers I-III and Paper V. As time progressed, we also 
considered gestational duration as an outcome variable in Papers III-V. Among 
these, Paper IV was the only paper in which gestational duration was analyzed
as a continuous variable. Section 4.6.1 to 4.6.5 briefly summarizes the 




In Paper I, 19 women with spontaneous PTD (cases) were compared to 118 
randomly selected women with delivery at gestational weeks 38+0 to 41+6
(controls). Women with severe chronic diseases were excluded from analysis. 
4.6.2 Paper II
The selection process of women for Paper II was similar to that of Paper I. It 
reports on 24 cases and 40 controls, who were randomly selected among 
women with a delivery at gestational weeks 38+0 to 41+6. As in Paper I, 
women with severe chronic diseases were excluded from analysis. 
4.6.3 Paper III
Paper III is the one that covers most of the spontaneous PTD cases. It was 
performed as a three-stage experiment, consisting of an exploratory phase 
followed by a validation phase and a replication phase. The two first phases
reported on essentially the same cohort of women as in Paper II, but with the 
exclusion of four women due to analytical issues, leaving 22 cases and 37 
controls. The replication phase was based on an independent selection of 
samples from the cohort, consisting of 20 cases and 40 matched controls. The
preceding and subsequent control of each case was chosen based on date of 
sampling and the following criteria; a) maternal age at sampling (± 2 years), 
b) parity (primiparous/multiparous), c) gestational age at sampling (± 3 days),
and d) whether the pregnancy was conceived using IVF (yes/no). Controls
were limited to women delivering between 38+0 and 41+6 gestational weeks.
Women with certain maternal diseases and fetal complications were excluded
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Gestational duration of the cohort according to previously described sub-group 
classifications in setion 2.5.4 and 2.4.1, respectively, are presented in Table 8 
(spontaneous PTD) and Table 9 (term delivery). The rate of extremely, 
severely and moderately PTD is slightly below the average while the group of 
women with a late or near-term PTD is more than 10 percentage points above 
average. As expected, the majority of women delivering at term were at full 
term.    
Table 2. Subgroups of PTD (n=76) with the rate presented being within the 
PTD interval. The overall rate represents the distribution of the study cohort 
(n=1178)  
Definition Rate; n (%) Overall rate (%) 
   
Extremely PTD 3 (3.9) 0.3 
   
Severely PTD 9 (11.8) 0.8 
   
Moderately PTD 10 ( 13.2) 0.9 
   
Late or near-term PTD 54 (71.1) 4.6 




Table 3. Subgroups of term deliveries in the study cohort (n=1178) with the 
rate presented being within the term interval. The overall rate represents the 
distribution of the study cohort 
Definition Rate; n (%) Overall rate (%) 
   
Early term 288 (26.1) 24.4 
   
Full term 557 (50.5) 47.3 
   
Late term 187 (17.0) 15.9 
   
Post-term 70 (6.4) 5.9 
   
 
Fig.9 presents the indication for the amniocenteses in the whole cohort 
(n=1218). As expected, the most common indication was advanced maternal 
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(controls). Women with severe chronic diseases were excluded from analysis. 
4.6.2 Paper II
The selection process of women for Paper II was similar to that of Paper I. It 
reports on 24 cases and 40 controls, who were randomly selected among 
women with a delivery at gestational weeks 38+0 to 41+6. As in Paper I, 
women with severe chronic diseases were excluded from analysis. 
4.6.3 Paper III
Paper III is the one that covers most of the spontaneous PTD cases. It was 
performed as a three-stage experiment, consisting of an exploratory phase 
followed by a validation phase and a replication phase. The two first phases
reported on essentially the same cohort of women as in Paper II, but with the 
exclusion of four women due to analytical issues, leaving 22 cases and 37 
controls. The replication phase was based on an independent selection of 
samples from the cohort, consisting of 20 cases and 40 matched controls. The
preceding and subsequent control of each case was chosen based on date of 
sampling and the following criteria; a) maternal age at sampling (± 2 years), 
b) parity (primiparous/multiparous), c) gestational age at sampling (± 3 days),
and d) whether the pregnancy was conceived using IVF (yes/no). Controls
were limited to women delivering between 38+0 and 41+6 gestational weeks.
Women with certain maternal diseases and fetal complications were excluded




Paper IV is the only paper with a cohort study design, analyzing gestational 
duration as a continuous variable. The final cohort that consisted of 784 
women, constituting the largest cohort among the constituent papers. To 
distinguish the phenotype, the study focused on women with spontaneous onset 
of labor, both at term and at preterm.
4.6.5 Paper V
In Paper V, matched case-control pairs were used. Only women with a delivery 
at gestational weeks 38+0 to 41+6 were considered eligible controls, as of 
Papers I-III. Women with sampling or analytical aberrations were excluded, as 
were women who had chronic diseases that could potentially affect results. The 
preceding and subsequent control of each case was chosen based on date of
sampling and the following criteria; 1) gestational age at sampling (± 3 days), 
2) parity (nulliparous/multiparous), 3) IVF (yes/no), 4) maternal age at samp-
ling (± 2 years), 5) BMI group and 6) pregnancy complications or maternal
chronic diseases. The final analysis included 36 cases and 36 controls.
4.7 Sample collection and processing
Amniocentesis was performed by an obstetrician under real-time sonography 
guidance. A 22-gauge (0.7x120 mm) lumbar cannula was inserted trans-
abdominally into the amniotic sac and 10-20 mL of amniotic fluid was 
extracted. An additional 3 mL was collected from consenting participants. 
Transplacental amniocentesis was avoided if possible and women were 
recommended to avoid physical activity for the rest of the day. 
Shortly after sample collection, the amniotic fluid was placed in a refrigerator 
at 4-8 ºC until it was processed later that day. Samples were then centrifuged 
for 20 minutes at 12 000 g at 4ºC (Fig.10). The supernatant was separated from 
the pellet and divided into aliquots of 200 µL. The pellet was suspended in 
MATERIAL AND METHODS
xl
phosphate-buffered saline, a water-based salt solution commonly used in 
biological research, and divided into aliquots of 500 µL. The aliquots were 
frozen and stored at -80ºC in the local biobank at Sahlgrenska University 
Hospital/Östra. A standard operating procedure, consisting of detailed step-by-
step methodological descriptions, quality manuals and protocols for
documentation, was developed. This was carefully followed by all members of 
the research group in order to achieve uniformity of performance and to ensure 
a high-quality output without origins, causes and influences that could be 
affected. 
Figure 10. Amniotic fluid sample collection and processing. Illustration: 
Jan Funke.
4.8 Amniotic fluid analyses
Clinical genetic analysis of the amniotic fluid samples were generally 
performed with quantitative fluorescent-polymerase chain reaction (QF-PCR), 
which analyzes chromosomes 13, 18, 21 and the sex chromosomes, accounting
for the majority of chromosomal abnormality cases. In some cases, especially 
with a family history of chromosomal abnormality or genetic disease, a full 
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The amniotic fluid collected for research was successively analyzed in batches. 
Proteins, inflammatory markers and metabolites were analyzed using targeted 
hypothesis-driven approaches (Luminex, Meso-Scale and enzyme-linked 
immunosorbent assay (ELISA)), as well as broad untargeted hypothesis-
generating approaches (proteomics and metabolomics), to optimize the 
chances to detect biomarkers associated with spontaneous PTD (Fig.11) and 
gestational duration (Fig.12).  
Figure 11.  Analyses of mid-trimester amniotic fluid in relation to spontan-












Luminex and MesoScale analyses were performed at Statens Serum Institut 
(SSI) in Copenhagen, Denmark. Proteomics analyses were performed at 
Charles University, Hradec Kralove, Czech Republic, and metabolomics 
analyses were performed at Chalmers Mass Spectometry Infrastructure at 
Chalmers University of Technology, Gothenburg, Sweden. ELISA analyses 
were performed at the Perinatal Laboratory, Sahlgrenska University Hospital/ 
Östra, Gothenburg, Sweden. 
 
4.8.1 Multiplex analyses 
 
The hypothesis-driven analyses were developed to solely focus on 
inflammatory and immunological biomarkers. Due to the complexity of the 
immune system and the possible network of biomarkers contributing to 
spontaneous PTD, we performed multiplex analyses, which allow simul-
taneous measurement of multiple analytes (249). Paper I is based on the first 
analysis ever of the cohort. When these samples were to be analyzed in 2011, 
Luminex xMAP technology, previously described in several publications 
(249-253), was the primary choice for multiplex analyses at SSI. Briefly 
described, it is a technology based on flowmetric analysis of microbeads 
encoded with two different fluorescent colors of diverse intensities. Each bead 
is coated with specific capture antibodies against one of the analytes of interest. 
The beads are incubated with the samples and the antigens bind to the capture 
antibodies. The samples are washed to remove excess material and a solution 
containing antibodies and detector molecules that determines the intensity of 
the fluorescence is added. The new antibodies bind to the antigens on the 
beads’ antibodies. Samples are incubated again, and the beads pass a Photo 
Multiplier Tube detector with lasers that read the fluorescence, proportional to 
the concentration of antigens in the sample. Data are subsequently processed. 
Due to their unique fluorescence characteristics, assays for several analytes can 
be performed simultaneously on different sets of beads.  
In 2017, we planned for a larger multiplex study with gestational duration as 
the main outcome (Paper IV). We used a newly developed technology, Meso-
Scale Discovery, as it had certain advantages over the Luminex technology. 
The Meso-Scale technology has been presented in publications (249, 253). 
Briefly, Meso-Scale combines electrochemiluminescence and MULTI-
ARRAY technology. The detection system uses plates fitted with up to ten 
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different capture antibody. The assay procedure is similar to that of ELISA but 
quicker; the electrode captures the analytes of interest with an analyte-specific 
secondary antibody. Labels, called SULFO-TAG, are conjugated to the 
detection antibodies. On electrochemical stimulation of the plate electrodes’ 
surface, the SULFO-TAG labels emit light that allows determination of the 
analyte concentration relative to the particular electrode. The combination of 
electrochemiluminescence and MULTI-ARRAY technology bring speed and 
high density of information to biological assays.   
The analytes selected for the Luminex assay panel were proteins previously 
identified as associated with term delivery and spontaneous PTD in the late 
second or third trimester by our group, or linked to neurological developmental 
abnormality (134, 254, 255). The panel used for Meso-Scale analyses was 
based on the Luminex panel but further developed to include a few DAMPs 
(93). These were partly selected, based on the classification of Garg A et al. 
(256), to explore sterile IAI (96, 97) to some extent. The panel was finally 
adjusted and developed based on what was technically, financially and 
realistically feasible, as well as on the availability of commercial kits. Table 
10 presents the selected proteins in the respective multiplex analyses with their 
main function roughly categorized into the following subgroups; cytokines, 
chemokines or other inflammatory proteins.  
Table 10. The selected proteins in the respective panels; a part of the 
Luminex analyses, b part of the Meso-Scale Discovery analyses. Data from 
the UniProt Con-sortium (257) and Meso-Scale Diagnostics (258) 
Short protein 
name Protein name 
a/b Main function 
   
Adiponectin a,b Adiponectin  Cytokine 
   




   
CRP a,b C-reactive protein  Other inflammatory 
protein 
   
GM-CSF a,b Granulocyte-macrophage 
colony stimulating factor  
Cytokine 
   









HSP70 b Heat shock protein 70  Other inflammatory 
protein 
   
IFN- ƴ  a Interferon gamma  
 
Cytokine 
IGFBP-1 a,b Insulin-like growth factor-
binding protein 1  
Other inflammatory 
protein 
   
IGFBP-3 a Insulin-like growth factor-
binding protein 3  
Other inflammatory 
protein 
   
IL-1β a,b Interleukin-1 beta  Cytokine 
   
IL-6 a,b Interleukin-6  Cytokine 
   
IL-6RA a Interleukin-6 receptor subunit 
soluble    
Cytokine 
   
IL-8 a,b Interleukin-8  Chemokine 
   
IL-10 a,b Interleukin-10  Cytokine 
   
IL-12 b Interleukin-12  Cytokine 
   
IL12A a Interleukin-12A  Cytokine 
   
IL-17 a,b Interleukin-17  Cytokine 
   
IL-18 a,b Interleukin-18  Cytokine 
   
Leptin a Leptin  Cytokine 
   
MCP-1 
(CCL2) a,b 
Monocyte chemotactic protein 
1 (C-C motif chemokine 2)  
Chemokine 
   
MIF a Macrophage migration 
inhibitory factor  
Cytokine 
   
MIP-1α  
(CCL3) a,b  
Macrophage inflammatory 
protein 1α (C-C motif 
chemokine 3)  
Chemokine 




protein-1 beta (C-C motif 
chemokine 4)  
Chemokine 





MMP-8 b Matrix metalloproteinase-8 
[Neutrophil collagenase]  
Other inflammatory 
protein 
   
MMP-9 a,b Matrix metalloproteinase-9  Other inflammatory 
protein 
   
NT-3 a Neurotrophin-3  Other inflammatory 
protein 
   
RANTES a,b T-cell-specific protein 
RANTES [C-C motif 
chemokine 5]  
Cytokine/chemokine 








   
TGF-β1 b Transforming growth factor 
beta-1  
Cytokine 
   
TNF-α a,b Tumor necrosis factor α  Cytokine 
   
TNF-β  
(LT-α) a,b 
Tumor necrosis factor  
(Lymphotoxin-alpha)  
Cytokine 
   
TNF-RI a Tumor necrosis factor receptor 
1  
Cytokine 
   
TREM-1 a Triggering receptor expressed 
on myeloid cells 1  
Other inflammatory 
protein 
   
Thrombo-
spondin-1b 
Thrombospondin-1 Other inflammatory 
protein 










4.8.2 “Omics” analyses 
 
High throughput techniques, collectively referred to as “omics” techniques 
(259) and “high-dimensional biology”, allow data mining of complex datasets 
by simultaneous examination in a biological sample. Changes in the DNA are 
studied by genomics, in the microRNA by transcriptomics, in proteins by 
proteomics and in metabolites using metabolomics. These techniques, 
individually or in combination, aims to increase the understanding of the 
physiology and mechanisms of pathological conditions or diseases (260-262). 
Genomics study the expression of genes while proteomics study the protein 
expression. Metabolomics, however, is used to investigate the consequences 
of the activity of these genes and proteins. Due to the multi-layered responses 
to infection and damage detectable by metabolomics, the method may be 
particularly interesting in the investigation of pathways and processes involved 
in inflammatory responses (263).  
These “omics” techniques are broad and untargeted hypothesis-generating 
methods. Two of the techniques, proteomics and metabolomics, were applied 
in the constituent papers of this thesis (Papers II, III and V). 
Proteomics provide insight into the proteins’ quantity and exploration of the 
proteomes, covering proteins’ overall composition, structure and activity, 
differing between cells and over time. The mass spectrometry-based method 
applied in Papers II and III labeled proteins by stable isotope tags followed by 
liquid chromatography–mass spectrometry (LC-MS). Proteins were digested 
and multidimensional LC was used to physically separate the multiple 
components (264, 265) of the amniotic fluid. Finally, samples were analyzed 
with tandem MS (266), using its mass analysis capabilities which reveals the 
structural identity of the individual components with high molecular specificity 
and detection sensitivity. The individual capabilities of each method enhance 
one another synergistically (264, 265). The peptide identification and 
quantitation and recorded fragmentation spectra were evaluated in Proteome 
Discoverer software and Max Quant software, respectively, integrating a false 
discovery rate analysis, and thereafter compared against the human UniProt 
database. The sample ratio to global internal standard were calculated based 
on the intensities of iTRAQ reporter ions, which were corrected using isotope 
factors supplied with the iTRAQ kit. The identified proteins were further 
filtered in order to obtain the final dataset. Both a pooled samples strategy 
(Paper II) and analysis of individual samples (Paper III) were applied. Since 
the delivery is inflammatory conditioned, many of the proteins that were 





4.8.2 “Omics” analyses 
 
High throughput techniques, collectively referred to as “omics” techniques 
(259) and “high-dimensional biology”, allow data mining of complex datasets 
by simultaneous examination in a biological sample. Changes in the DNA are 
studied by genomics, in the microRNA by transcriptomics, in proteins by 
proteomics and in metabolites using metabolomics. These techniques, 
individually or in combination, aims to increase the understanding of the 
physiology and mechanisms of pathological conditions or diseases (260-262). 
Genomics study the expression of genes while proteomics study the protein 
expression. Metabolomics, however, is used to investigate the consequences 
of the activity of these genes and proteins. Due to the multi-layered responses 
to infection and damage detectable by metabolomics, the method may be 
particularly interesting in the investigation of pathways and processes involved 
in inflammatory responses (263).  
These “omics” techniques are broad and untargeted hypothesis-generating 
methods. Two of the techniques, proteomics and metabolomics, were applied 
in the constituent papers of this thesis (Papers II, III and V). 
Proteomics provide insight into the proteins’ quantity and exploration of the 
proteomes, covering proteins’ overall composition, structure and activity, 
differing between cells and over time. The mass spectrometry-based method 
applied in Papers II and III labeled proteins by stable isotope tags followed by 
liquid chromatography–mass spectrometry (LC-MS). Proteins were digested 
and multidimensional LC was used to physically separate the multiple 
components (264, 265) of the amniotic fluid. Finally, samples were analyzed 
with tandem MS (266), using its mass analysis capabilities which reveals the 
structural identity of the individual components with high molecular specificity 
and detection sensitivity. The individual capabilities of each method enhance 
one another synergistically (264, 265). The peptide identification and 
quantitation and recorded fragmentation spectra were evaluated in Proteome 
Discoverer software and Max Quant software, respectively, integrating a false 
discovery rate analysis, and thereafter compared against the human UniProt 
database. The sample ratio to global internal standard were calculated based 
on the intensities of iTRAQ reporter ions, which were corrected using isotope 
factors supplied with the iTRAQ kit. The identified proteins were further 
filtered in order to obtain the final dataset. Both a pooled samples strategy 
(Paper II) and analysis of individual samples (Paper III) were applied. Since 
the delivery is inflammatory conditioned, many of the proteins that were 




one way or another. However, due to the untargeted approach, proteins may 
also be related to inflammation or immunology by other pathways such as 
apoptosis or necrosis.  
The rapid rise and application of proteomics has resulted in the identification 
of many potential biomarkers for a number of specific conditions. This 
abundance highlights the importance of validation in order to confirm or 
disprove the proteins’ potential. This was applied to both Papers II and III, 
where the results from the exploratory proteomics phase were validated 
(Papers II and III) and replicated (Paper III).  
As the inflammation can alter the local and systemic metabolic profile (267), 
metabolomics technique was also applied to the cohort (Paper V), with the aim 
to investigate processes involved in inflammatory pathways of particularly 
spontaneous PTD but also gestational duration. Metabolomics is used to study 
small-molecule metabolite profiles (268), end products of cellular processes 
(269) such as metabolic intermediates, hormones and other signaling 
molecules (270, 271). Several metabolomics techniques are available, of which 
LC-MS was used to identify and quantify metabolites in the amniotic fluid 
samples included in Paper V. Identification is based on the distinct patterns 
into which analytes fragment, which can be regarded as a mass spectral 
fingerprint. There are libraries that facilitate identification of a metabolite 
according to this fragmentation pattern. Metabolomic examination of 
interactions between inflammation and metabolic changes during gestation 
may increase our understanding of the etiology of spontaneous PTD (267). It 
is also a promising method for biomarker discovery (272, 273), for which 
amniotic fluid, rich in metabolites, becomes an especially interesting biological 
matrix (267).  
 
4.8.3 Singleplex analysis 
 
The final targeted analysis was singleplex, using ELISA to validate potential 
biomarkers identified in the exploratory phases of Papers II and III, as well as 
to replicate proteins from the validation phase of Paper III. In Paper II, only 
CRP was subjected for validation (protein name and main function is presented 
in Table 10). Table 11 presents the proteins that were validated in Paper III 
with their protein accession number and main function roughly categorized 
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NGAL Neutrophil gelatinase-associated 
lipocalin 
  





ELISA is the most commonly applied biochemical assay to determine 
quantitative protein changes in a sample (274) and it is also used for analysis 
of a single key target protein (249). To detect the presence of a protein in a 
liquid sample with ELISA, solid-phase enzyme immunoassay is applied, in our 
case in plates with 96 wells. Antibodies in the wells are specifically targeted 
for a particular antigen, the protein of interest. Antigens in the sample attach 
to the surface, where they bind to matching antibodies linked to enzymes, 
applied over the surface. A substance containing the enzyme's substrate is then 
added, leading to a color change in the well. Light is thereafter sent through 
the well by spectrophotometer, and the amount of absorbed light is measured. 
The darker the color, the higher the antigen concentration (275, 276). 
Samples undergoing ELISA were thawed, briefly centrifuged, mixed in a 
vortex and diluted to different concentrations. The dilution was tested 
thoroughly, based on the lowest dilution at which the protein can still be 
detected. Dilution also aimed at preventing protein-protein interactions. When 
performing analyses such as ELISA, there are factors and challenges that must 
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4.9 Statistical analyses 
 
The statistical analyses were performed in close collaboration with an 
experienced statistician. The following software programs were used: SPSS 
20.0, 24.0 and 25.0 for Windows XP OS (SPSS Inc, USA), MedCalc 
17.7.0  (MedCalc software, Belgium), R version i386 3.0.2 (R version 3.0.2 
(2013-09-25), The R Foundation for Statistical Computing, Platform i386-
w64-mingw32/i386 (32-bit), R version 3.3.1, and MUVR R package v 0.0.973. 
Graphical presentation of data in Paper III was designed with the Software 
Perseus version 1.5.1.6.  
In all constituent papers, Mann–Whitney U test or the Student T-test were used 
to compare continuous variables. These variables were presented as median 
and interquartile range (IQR: 25th; 75th percentiles). Categorical data were 
analyzed with the Chi-square test, and in cases of < five individuals at any 
level, Fisher’s exact test was used. Variables were presented as total count 
(numbers) and frequency distribution (%).  
Before analyzing the data, a logarithmic transformation was performed to 
decrease the effect of outliers and to approach normal distribution, which 
makes analysis easier. In Papers I and IV, in which multiplex technologies 
were applied, results were adjusted for plate effects as a potential confounder. 
Bonferroni correction for multiple comparisons was also performed. In all of 
the constituent papers, differences were considered statistically significant at  
p < 0.05 using a two-sided alternative hypothesis.  
In Papers I and II, the control group was selected by randomization. In Paper 
I, differences between cases and controls were analyzed using analysis of 
covariance (ANCOVA). This was also the case in Paper III, in which 
ANCOVA or Student’s t-test was used to compare mean protein 
concentrations in cases and controls in the exploratory and validation phases. 
Furthermore, the Pearson correlation was used to analyze correlations between 
protein concentrations or intensity ratio and gestational age at sampling and 
gestational duration, respectively, for both cohorts in Paper III. The possible 
influence of gestational age at sampling was also investigated in Papers IV and 
V. We adjusted for this variable in all three cases, as there was a strong 
association between gestational age at sampling and protein concentrations.  
A linear mixed model was applied for the replication phase with matched 




V, in which a multivariate analysis was undertaken with unbiased variable 
selection within repeated double cross-validation. Analysis of spontaneous 
PTD compared with controls was performed as case/control, pair-dependent 
multilevel analyses with log-fold change between cases and controls as 
independent variables. Random forest regression models were performed for 
association between amniotic fluid metabolome and gestational age at 
sampling and gestational duration at delivery. Statistical significance of 
multivariate models was assessed using permutation.  
Paper IV differed from the others as this was the only study in which 
gestational duration was analyzed as a continuous variable. It was also the only 
study in which we selected covariates for which to adjust based on previously 
reported associations with spontaneous PTD or gestational duration. In the 
other papers, we instead analyzed whether these and other co-variates affected 
the outcome and, based on the results, we adjusted for the ones that did. The 
co-variates in Paper IV were maternal age at sampling, parity, smoking at first 
prenatal visit and IVF. Initially, linear regression was used to adjust protein 
concentrations for gestational age at sampling, experimental factors (plate 
effects) and year of sampling. A Cox regression analysis of the entire study 
cohort was applied on each of the separate amniotic fluid protein 
concentrations to explore possible associations with gestational duration. As 
we were interested in ascertaining whether findings were mostly related to 
spontaneous PTD or term delivery, Cox regression was censored at 259 days 
(37+0 gestational weeks) or longer. Based on the results, linear regression 
models were applied again to evaluate associations between protein 
concentrations and gestational duration in women with spontaneous onset of 
labor at term. Finally, linear regression was used to obtain an effect estimate 
of days/standard deviation (SD). The associations were robust independently 
of the choice of statistical model. The Cox regression model is a natural choice, 
rather than the linear model, for modeling survival outcome, while detecting 
markers with time-varying effects.   
Power calculations have not been performed in any of the Papers. In a cohort 
study like this, we rather had to do the analyses based on the actual numbers 
since we would hardly have been able to affect the actual numbers. Only in 
Paper I, a power analysis was used to calculate the smallest effect size possible 
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5.1 Potential biomarkers associated with gestational 
duration 
 
Potential biomarkers associated with gestational duration were examined in 
Papers III-IV. In Paper III, lower concentrations of neutrophil gelatinase-
associated lipocalin (NGAL) and plasminogen activator inhibitor 1 (PAI-1) 
were associated with gestational duration, but neither association was 
replicated in a second independent cohort. In Paper IV, we found that increased 
concentrations of thrombospondin-1, macrophage inflammatory protein-1 beta 
[C-C motif chemokine 4] (MIP-1β) and S100A8, respectively, were associated 
with lower gestational duration in women with spontaneous onset of labor at 
term, after Holm-Bonferroni correction. However, the effect was minor, with 
a decrease in gestational duration by 0.9-1.1 days if concentrations increased 
by 57% to 104%. No biomarkers associated with gestational duration were 
identified in Paper V.  
 
5.2 Potential biomarkers of spontaneous preterm 
delivery 
 
In Paper I, nominally significantly lower concentrations of adiponectin, GM-
CSF and macrophage migration inhibitory factor (MIF) was found in amniotic 
fluid from women with spontaneous PTD, compared to women who delivered 
at term, after adjustment for plate effects. After a conservative Bonferroni 
correction, no significance remained. In Paper II, CRP emerged as an 
interesting biomarker with higher concentrations in women with spontaneous 
PTD than in women with term delivery. However, its potential was not verified 
with ELISA. In Paper III, we identified nine potential candidates that were 
related to spontaneous PTD group. Two of these, NGAL and PAI-1, were 
validated in the same cohort, with lower concentrations in the spontaneous 
PTD than in the term delivery group. However, neither association was 





were associated with spontaneous PTD were identified in Papers I-III, and no 
potential biomarkers associated with spontaneous PTD emerged in Paper IV 
or V. 
 
5.3 The association with gestational age at 
sampling 
 
One of the findings, reported especially in Papers IV and V, was that amniotic 
fluid protein concentrations changed with gestational age at sampling. The 
greatest effect was seen in Paper IV, in which thrombospondin-1 and HMG-1 
were found to have the strongest associations. Protein concentrations increased       




















6.1 General discussion 
 
The results of this thesis are generally interesting since there is a biological 
rationale for several of these candidate proteins being linked to spontaneous 
PTD, gestational duration and inflammation. Interestingly, certain proteins 
emerged in several studies, regardless of study design. Insulin-like growth 
factor-binding protein (IGFBP)-7, NGAL and PAI-1, identified as being 
associated with both spontaneous PTD and gestational duration in the 
exploratory phase of Paper III, also emerged as three of the 19 downregulated 
proteins in Paper II. They were, however, not among the top ten most 
dysregulated proteins. In Paper IV, protein S100-A8 was significantly 
associated with gestational duration in women with a spontaneous onset of 
labor at term. This protein was also identified among the 19 downregulated 
proteins reported in Paper II.   
Many of the women, especially cases of spontaneous PTD, were analyzed in 
several of the papers. Between Papers I and IV, there was, consciously, an 
overlap of 148 women, in which amniotic fluid was analyzed using both 
multiplex methods. Two of the three nominally significantly proteins of Paper 
I, adiponectin and granulocyte-macrophage colony stimulating factor, were 
also included in the panel of Paper IV. However, none of them were 
significantly associated with either spontaneous PTD or gestational duration in 
Paper IV, in line with the findings of Paper I where no significant differences 
among women with a spontaneous PTD compared to women with a delivery 
at term remained after Bonferroni correction for multiple comparisons. 
Women excluded from the respective analyses, especially in relation to 
maternal disease, were addressed specifically for each constituent study based 
on conditions that might affect the analysis (e.g. were women with diabetes 
excluded from the metabolomics analyses) or that might have caused 
spontaneous PTD (e.g. uterine malformations). The exclusion of the first week 
of the early term group as well as the exclusion of the post-term group from 
our controls were supported by the theory that the subgroups within the term 
interval have a somewhat different etiology and rate of adverse neonatal 






who had undergone IVF, we were consistent throughout all papers. These 
women were not excluded from analyses, although both previous PTD (277, 
278) and IVF have been described as independent predictors of PTD in 
previous studies (279, 280), as well as in a meta-analysis (281). Women with 
a spontaneous PTD, which consisted of both PTL and PPROM cases, were not 
stratified. Our opinion was that the groups were too small for such exclusions 
or stratifications.  
Internal or external environmental, nutritional and genetic factors might have 
varied over time and influenced the results. The technical environment 
develops fast, and new technologies can thus be applied within the same 
project. This was indeed the case with the targeted analyses; Luminex techno-
logy was eventually supplemented by the introduction of Meso-Scale techno-
logy. Due to the long-term nature of the project, the issue of storage duration 
of the samples, collected over a 10-year period, should be addressed. There is 
limited research concerning whether such a long storage period affects protein 
concentrations in amniotic fluid. In a study from 1998, the stability of 
angiogenin and IL-6 in paired mid-trimester amniotic fluid samples was 
investigated. Despite optimal freezing conditions, both proteins’ concentra-
tions decreased significantly during the one-year storage period (282). This 
indicates that the proteins may not be stable. However, in Paper IV, only six 
of the 26 proteins examined were affected by storage time. In a study by our 
group, investigating the stability of IL-6 based on different pre-processing 
conditions, results indicate that this is a stable protein (283). Further research 
is thus needed to determine the effect of storage time and other factors on 
protein concentrations.  
 
6.2 Gestational duration 
 
Interestingly, NGAL and PAI-1 were associated with both gestational duration 
and spontaneous PTD in Paper III, although the findings were not replicated in 
a second independent cohort. The original case-cohort design in Papers III and 
V complicated the identification of proteins associated with gestational 
duration, as the conditions were not really optimal for this variable.  
Paper IV consisted of the largest cohort among the constituent papers of this 
thesis, which provided better conditions and power to detect differences. 
Further, this was the only study using a pure cohort design in which gestational 
 
 
duration was examined as a continuous variable. In Paper IV, seven biomarkers 
were significantly associated with gestational duration at a false discovery rate 
of <0.1; thrombospondin-1, MIP-1β, S100A8, IL-18, MIP-1α, IGFBP-1 and 
HMG-1. The increases in thrombospondin-1, MIP-1β and S100A8 survived 
Bonferroni correction. The results may primarily be relevant in cases of late or 
near-term spontaneous PTD, representing 71.1% of our PTD cohort, with a 
median gestational duration (IQR) of 35+6 (33+5 – 36+4) weeks among 
women with spontaneous PTD. Late spontaneous PTD is associated with less 
significant neonatal morbidity and mortality compared to spontaneous PTD in 
the earlier gestational intervals (6). The findings strengthens that this group of 
women share some common pathways with women who have a spontaneous 
onset of labor at term. It also adds to the concept of a pregnancy clock, which 
may be reflected in amniotic fluid.  
DAMPs are significant components of the inflammatory processes preceding 
the spontaneous onset of labor at term. Several DAMPs, specifically amniotic 
fluid concentrations of HMG1, encoded by the high mobility group box 1 
(HMGB1) gene, have also been shown to be associated with preterm and term 
delivery (284-286). Relationships have been reported between DAMPs, in 
several tissues and biological fluids, and both preterm and term delivery. 
However, DAMPs are also part of the natural biological pregnancy processes, 
which must be taken into consideration, especially as sampling was performed 
at a gestational age during which major reorganization and remodeling occur 
at the feto-maternal interface, resulting in turn in increased DAMP 
concentrations. The observed changes could therefore potentially just reflect a 
normal biological process in a fully developed and functional uterine cavity. 
Gestational duration prediction based on these biomarkers is thus likely an 
indicator of a functional amniotic cavity. Either way, the values may indicate 
feto-placental growth and function and may generate hypotheses for further 
studies. It is self-evident that the sampling window, gestational weeks 14 to 
19, was quite narrow and it is thus unclear whether such correlations continue 
beyond 19 gestational weeks. Several gestational clocks have been described 
(15-19, 287), but based on a longitudinal study design with repeated sampling 
throughout gestation (16). Furthermore, the data concerning "percentage 
change per day" assumes that percentages changes in a linear fashion, a 
conclusion that cannot be drawn from our data. However, we are not aware of 
any publication where this association, adding to the concept of a pregnancy 
clock reflected in the amniotic fluid, has been described to the same extent as 





who had undergone IVF, we were consistent throughout all papers. These 
women were not excluded from analyses, although both previous PTD (277, 
278) and IVF have been described as independent predictors of PTD in 
previous studies (279, 280), as well as in a meta-analysis (281). Women with 
a spontaneous PTD, which consisted of both PTL and PPROM cases, were not 
stratified. Our opinion was that the groups were too small for such exclusions 
or stratifications.  
Internal or external environmental, nutritional and genetic factors might have 
varied over time and influenced the results. The technical environment 
develops fast, and new technologies can thus be applied within the same 
project. This was indeed the case with the targeted analyses; Luminex techno-
logy was eventually supplemented by the introduction of Meso-Scale techno-
logy. Due to the long-term nature of the project, the issue of storage duration 
of the samples, collected over a 10-year period, should be addressed. There is 
limited research concerning whether such a long storage period affects protein 
concentrations in amniotic fluid. In a study from 1998, the stability of 
angiogenin and IL-6 in paired mid-trimester amniotic fluid samples was 
investigated. Despite optimal freezing conditions, both proteins’ concentra-
tions decreased significantly during the one-year storage period (282). This 
indicates that the proteins may not be stable. However, in Paper IV, only six 
of the 26 proteins examined were affected by storage time. In a study by our 
group, investigating the stability of IL-6 based on different pre-processing 
conditions, results indicate that this is a stable protein (283). Further research 
is thus needed to determine the effect of storage time and other factors on 
protein concentrations.  
 
6.2 Gestational duration 
 
Interestingly, NGAL and PAI-1 were associated with both gestational duration 
and spontaneous PTD in Paper III, although the findings were not replicated in 
a second independent cohort. The original case-cohort design in Papers III and 
V complicated the identification of proteins associated with gestational 
duration, as the conditions were not really optimal for this variable.  
Paper IV consisted of the largest cohort among the constituent papers of this 
thesis, which provided better conditions and power to detect differences. 
Further, this was the only study using a pure cohort design in which gestational 
 
 
duration was examined as a continuous variable. In Paper IV, seven biomarkers 
were significantly associated with gestational duration at a false discovery rate 
of <0.1; thrombospondin-1, MIP-1β, S100A8, IL-18, MIP-1α, IGFBP-1 and 
HMG-1. The increases in thrombospondin-1, MIP-1β and S100A8 survived 
Bonferroni correction. The results may primarily be relevant in cases of late or 
near-term spontaneous PTD, representing 71.1% of our PTD cohort, with a 
median gestational duration (IQR) of 35+6 (33+5 – 36+4) weeks among 
women with spontaneous PTD. Late spontaneous PTD is associated with less 
significant neonatal morbidity and mortality compared to spontaneous PTD in 
the earlier gestational intervals (6). The findings strengthens that this group of 
women share some common pathways with women who have a spontaneous 
onset of labor at term. It also adds to the concept of a pregnancy clock, which 
may be reflected in amniotic fluid.  
DAMPs are significant components of the inflammatory processes preceding 
the spontaneous onset of labor at term. Several DAMPs, specifically amniotic 
fluid concentrations of HMG1, encoded by the high mobility group box 1 
(HMGB1) gene, have also been shown to be associated with preterm and term 
delivery (284-286). Relationships have been reported between DAMPs, in 
several tissues and biological fluids, and both preterm and term delivery. 
However, DAMPs are also part of the natural biological pregnancy processes, 
which must be taken into consideration, especially as sampling was performed 
at a gestational age during which major reorganization and remodeling occur 
at the feto-maternal interface, resulting in turn in increased DAMP 
concentrations. The observed changes could therefore potentially just reflect a 
normal biological process in a fully developed and functional uterine cavity. 
Gestational duration prediction based on these biomarkers is thus likely an 
indicator of a functional amniotic cavity. Either way, the values may indicate 
feto-placental growth and function and may generate hypotheses for further 
studies. It is self-evident that the sampling window, gestational weeks 14 to 
19, was quite narrow and it is thus unclear whether such correlations continue 
beyond 19 gestational weeks. Several gestational clocks have been described 
(15-19, 287), but based on a longitudinal study design with repeated sampling 
throughout gestation (16). Furthermore, the data concerning "percentage 
change per day" assumes that percentages changes in a linear fashion, a 
conclusion that cannot be drawn from our data. However, we are not aware of 
any publication where this association, adding to the concept of a pregnancy 
clock reflected in the amniotic fluid, has been described to the same extent as 






6.3 Spontaneous preterm delivery 
 
Five potential mid-trimester biomarkers of spontaneous PTD emerged in this 
project: adiponectin, GM-CSF and MIF in Paper I, and NGAL and PAI-1 in 
Paper III. All concentrations were lower among women with spontaneous 
PTD, compared to women with term delivery, but the findings did not survive 
Bonferroni correction or replication. In total, median concentrations of 18 of 
the 25 proteins analyzed in Paper I were lower, albeit not significantly, in the 
spontaneous PTD group, compared with controls (Paper I, Table 3). In Paper 
III, the majority of the potential biomarkers from the exploratory phase using 
LC-MS/MS proteomics could not be validated, and the findings of NGAL and 
PAI-1 could not be replicated. The findings are though novel and interesting 
as none of nine proteins from the exploratory phase have previously been 
evaluated in mid-trimester amniotic fluid, although they have previously been 
described as being associated with spontaneous PTD etiology among 
symptomatic women in later gestation. Moreover, expression of most of the 
proteins identified in all the constituent papers was decreased among women 
with spontaneous PTD. Decreased expression of many cytokines linked to host 
defense and inflammatory immune capacity have previously been described in 
mid-trimester plasma samples of healthy pregnancies (26). This may further 
reflect the high rate of late or near-term spontaneous PTD cases in our cohort, 
with a somewhat similar etiology as women with a spontaneous onset of labor 
at term. Infectious and/or inflammatory processes mainly correlate with early, 
particularly extremely, spontaneous PTD (159) and the earlier in gestation that 
delivery starts, the more likely the existence of other biological processes and 
mechanisms that cause onset of the normal delivery process. This further 
explains the somewhat weak associations in our studies for proteins previously 
reported as associated with spontaneous PTD.  
The Bonferroni correction is conservative, as in the case of Paper I. Some 
would recommend that it not be performed, but rather to leave it to the reader 
to judge whether the findings are clinically important or not. The risk if we 
correct is that we miss important differences, while the risk if we do not correct 
is the emergence of findings that do not exist.  
ELISA did not validate or replicate the findings of Paper III and there are 
several potential reasons for this. First and most importantly, the results of 
these two analyses are not comparable or even proportional to one another. The 
results from the exploratory phase yielded intensity ratios related to ionization/ 
separation, while ELISA yielded pure concentrations. Validation and replica-
 
 
tion were performed by ELISA, but there are other ways to validate and 
replicate potential biomarkers, i.e. using targeted proteomic analysis by 
selected or multiple reaction monitoring. There may also be technical and 
processing differences between the phases, as well as biological differences 
between the groups, that can explain why these findings were not 
validated/replicated. Furthermore, the cohorts originated from different years, 
and environmental conditions may have changed. The dynamic proteome may 
vary among cells. Its structure depends on a wide range of internal and external 
factors that were not completely controlled for in this study (or in any human 
study). Another possible reason that the results from the validation phase did 
not correlate with those from the replication phase is that we used matched 
samples for the replication cohort. Finally, at least in women with PPROM, 
there is a huge variance in protein concentrations, also after stratification 
according to MIAC and HCA, as well as in the absence of significant 
differences in clinical and demographical characteristics between groups.  
The multicollinearity of the Luminex data, in which the log concentrations of 
the three statistically significant proteins were strongly correlated (Paper I, 
Fig.2), must also be kept in mind. This is a problem as the effects of the 
proteins cannot be kept apart. However, it supports the hypothesis that a 
coordinated network, rather than a single factor, contributes to the occurrence 
of spontaneous PTD. Furthermore, the targeted multiplex technology analyses 
in Papers I and IV solely focused on inflammatory pathways, while spontan-
eous PTD has multifactorial pathophysiology. For instance, a multiplex study 
of mid-trimester amniotic fluid in women with a short cervix, that examined 
multiple pathways rather than a single mediator, found that a group of 
inflammatory mediators predicted spontaneous PTD (288). A key factor 
distinguishing that study from ours was that those women had a cervical length 
of ≤25 mm at the time of sampling. As cervical length was not measured in our 
cohort, the studies are not really comparable.  
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The dynamic environment in utero changes as pregnancy progresses. 
However, amniotic fluid samples from asymptomatic women in early 
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for biomarker discovery. The timing of cytokine release and the local 
environment in which they act as well as the presence of competing or 
synergistic elements, cytokine receptor density and tissue responsiveness to 
each cytokine may potentially differ during pregnancy. Further, as spontaneous 
PTD is caused by heterogeneous pathways, the respective optimal gestational 
ages may either overlap or diverse.  
Most of our samples were collected between the pro-inflammatory phase of 
the first trimester and early second trimester and onset of the anti-inflammatory 
phase of the second trimester. Numerous cytokines are present in mid-trimester 
amniotic fluid, and previously reported concentrations vary widely. This 
complicates the possibility to distinguish between “normal” values in healthy 
pregnancies and those in pathological pregnancies, which precludes the 
accurate interpretation of results. This is supported by the fact that we found 
lower concentrations of GM-CSF in mid-trimester amniotic fluid in women 
with spontaneous PTD in Paper I, while previous data report that the pregnancy 
itself elicits significantly increased concentrations of GM-CSF in all 




This cohort mainly represents a high-risk group of women with an increased 
risk of fetal chromosomal abnormalities. The proportion of pregnant women 
aged 35 years in the general Swedish population was 12% in 2015, compared 
to 74.0% (901/1218) in our cohort. It is therefore unclear how generalizable 
these data are when it comes to analyzing gestational duration in normal 
maternal age groups and low-risk pregnancies. Furthermore, the cohort 
represents women who, from a global perspective, are at low risk of PTD. Our 
data may therefore not be generalizable to a high-risk cohort. The gestational 
duration in the spontaneous PTD group is shifted far to the right. Although this 
does reflect the general rate, we recommend that our results mainly be 




6.6 Clinical importance 
 
The research reported in this thesis has contributed new findings, which are 
highly significant as they have increased insight into early changes in the 
amniotic fluid profile. These will hopefully serve as a basis for new hypotheses 
that may improve understanding of the molecular processes and other 
biological mechanisms contributing to the development of spontaneous PTD. 
New knowledge is valuable since PTD can cause neonatal mortality and severe 
morbidity leading to lifelong disability, and a reduction of the rate would have 
substantial effects on perinatal health and socioeconomic conditions.  
The studies presented in the more comprehensive papers (Papers III-V) are 
novel and unique when it comes to study design and the use of mid-trimester 
amniotic fluid samples. Finding biomarkers involved in the process in early 
pregnancy, long before PTD symptoms have arisen, will enable new strategies 
for early detection and intervention, treatment and prevention.  
The clinical translation value is, however, yet limited. The rationale for 
performing an invasive procedure such as an amniocentesis to predict 
pregnancy outcome is weak. It is nonetheless a first step towards biomarker 
discovery, which can eventually be applied in other more easily accessible 
biological compartments. The minor effects that we report, with an 
approximate one-day decrease in gestational duration in women with 
spontaneous onset of labor at term will lack value in a real clinical setting.  
 
6.7 Comparisons of study designs and analytical 
approaches 
 
6.7.1 Hypothesis-driven versus hypothesis-generating 
research 
 
Hypothesis-driven research, where a specific hypothesis is developed in a 
prospectively designed experiment with pre-defined groups, e.g. case/control, 
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biological research method. This type of experiment has played, and continues 
to play, an important role in science and medicine. The introduction of 
hypothesis-generating research has, however, enabled discoveries that would 
not have been possible with hypothesis-driven research. The two approaches 
thus complement each other. Hypothesis-generating research can provide key 
insights into biological and pathophysiological pathways by leading to results 
that were not initially intended or expected by the researchers. The novel 
theoretical basis that this type of research provides will have major impact 
when applied in clinical medicine (289). However, critical steps after the 
discovery of potential biomarkers are validation (290) and, when deemed 
appropriate, replication. The advantages of multiplex technology, compared to 
proteomics, included simultaneous analysis of a broad panel of potential 
biomarkers specifically selected for the purpose of the study and on known or 
hypothesized biomolecular pathways underlying PTD. Other advantages are 
the small sample volume needed, the cost-effectiveness and the minimal 
technological challenges, compared to omics techniques (248). 
 
 
6.7.2 Dichotomous versus continuous variables 
 
Categorizing (grouping) continuous variables may be helpful when data is 
presented, for instance in tables, and in interpreting results, but it is not 
necessary for statistical analysis (20). By dichotomizing data, i.e. cases/ 
controls, a substantial part of the data is lost, reducing the statistical power to 
detect associations between the variable and an outcome. Studies suggest that 
the diminished effect by dichotomizing a variable at the median reduces power 
equal to discarding one-third of all data (291, 292). This complicates research 
studies that already tend to use too small cohort, especially when examining 
rare outcomes. Dichotomization may also increase the risk of false positive 
results (293) and there is a substantial risk of underestimating the variation in 
outcome between groups as well within each group. Individuals close to, but 
on opposite sides of the cut-off point, may be characterized as being very 
different when in fact they are similar. Third, the analysis to two groups 
conceals and restricts all non-linear relationships between the variable and the 





6.7.3 Pooled versus individual samples 
 
Pooling samples means that multiple samples are homogenized into one 
sample for analysis (165). One advantage to this is that variations between 
patients, within patients or among sampling or processing conditions (such as 
between-year variation) may be reduced. It is also much less expensive than 
analysis of individual samples (294) and useful when the number of specimens 
is limited (295). The advantages of individual samples, on the other hand, are 
available information about variance and the freedom to choose an appropriate 
central measure (296, 297).  
 
6.7.4 Luminex versus Meso-Scale technology 
 
Both Luminex and Meso-Scale platforms are suitable for analyzing trends in 
multiple cytokine profiles. Quantitative differences are found but the relative 
differences are comparable. Luminex technology offers better precision, while 
Meso-Scale has higher sensitivity (249), better accuracy, and lower inter- and 
intra-assay variation. It also offers a broader dynamic range (249, 253), 
meaning that high and low expression concentrations can be measured without 
multiple sample dilution. As stated in Paper I, one protein, interferon (IFN)-ƴ, 
was only detected in 0.7% of the samples and was therefore excluded from the 
analysis. This can happen if there is a broad range of proteins concentrations 
within the same sample. The Luminex assay is the multiplex technology with 
the lowest range, which entails difficulties in simultaneously quantifying low 
and high concentrations of compounds, with loss of accuracy especially in the 
former case (249). The Meso-Scale platform, which has better low 
concentration accuracy (249, 298), might have detected IFN-ƴ better. 
 
6.7.5 Multiplex versus singleplex technology 
 
Compared to multiplex technologies, which allow simultaneous wide-range 
screening of multiple analytes in small sample volumes (298), ELISA enables 
the analysis of a single key target protein (249). Several analytes can be 
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more time-consuming and costly and require a larger sample volume, which 
would be challenging if the source of samples is small (298). However, one 





The value of this research project lies in the fact that it was performed on mid-
trimester (14-19 gestational weeks) amniotic fluid samples obtained via trans-
abdominal amniocentesis from asymptomatic women. The size of the cohort, 
with a lost to follow-up rate (including missing data) of only 0.8% (10/1218), 
comprehensive databases with clinical variables, systematic processes and 
standardized methodology for sample collection and processing and the 
number of available aliquots, is unique. The major strengths are the well-
designed studies, using high-capacity techniques such as proteomics and 
metabolomics and multiplex approaches, which may be a key to increased 
understanding of spontaneous PTD, detection of novel biomarkers and to 
obtaining a complete picture of the process (172, 248).  Collection of samples 
at this gestational age is becoming increasingly rare due to the introduction of 
NIPT, and new cohorts like this are thus unlikely in future.   
The pathways underlying spontaneous PTD and the factors involved in the 
onset of labor were examined with a variety of different techniques involving 
both targeted and non-targeted approaches. This should be considered a 
strength, as it increases the chances of identifying normal and pathological 
processes.  
A major strength of this project is the high level of data accuracy. In all 
constituent studies, we collaborated with an experienced statistician and the 
statistical analyses were thus very thorough. Technical analyses were conduct-
ed in collaboration with research groups, rather than just using services to 
undertake the analyses, in order to extract maximal effects of the data and to 
be able to discuss findings. This had a major impact on our research.  
The database work and medical records reviews were undertaken meticulously 
by experienced midwives or medical students involved in research. The 
selection of groups was also meticulous and undertaken stepwise, in order to 
ensure data accuracy. Results of the exploratory proteomics studies were 
 
 
validated/replicated, which is otherwise frequently neglected. The fact that 
three proteins were disqualified from validation in Paper III should also be 
regarded as a sign of seriousness and accuracy, as a factor present within the 
amniotic fluid samples might have caused matrix interference. This might in 
turn have confounded interpretation of results causing bias.  
Another major strength is that this was a team-oriented multidisciplinary 
project in which the team members shared responsibility for the project but 
contributed different skills and responsibilities. These interdisciplinary 
collaborations led to optimized and efficient use of available resources. I have 
been involved in this long-term and extensive project since the very beginning 
and throughout all phases, including conception, acquiring funding, 
development, applications, planning and execution. This has led to substantial 
continuity, which must be regarded as a strength.  
 
6.9  Limitations 
 
The most important limitation is that women undergoing mid-trimester genetic 
amniocenteses constitute a highly selected population, as they are of a more 
advanced maternal age and have a higher risk of fetal chromosomal 
abnormalities than the overall population. This causes selection bias. Such 
mid-trimester amniotic fluid samples can, however, only be collected in 
line with clear clinical indications, such as genetic testing. By excluding 
women with known or suspected fetal abnormalities from the study and 
women with confirmed fetal abnormalities from analysis, bias was 
addressed to some extent.  
Of all the women who underwent a mid-trimester genetic amniocentesis during 
the study period, 24.2% were ineligible and 48.5% of  the eligible women were 
excluded. An important limitation is the lack of information about these 
women. In retrospect, it would have been preferable to ask all women 
presenting for mid-trimester genetic amniocentesis for permission to review 
their medical records. Questionnaires regarding dietary patterns and physical 
activity, collection of blood, saliva or urine samples (possibly reflecting the 
intrauterine environment as well as amniocentesis), or an ultrasound 
assessment of the cervix are other factors that might have complemented our 





more time-consuming and costly and require a larger sample volume, which 
would be challenging if the source of samples is small (298). However, one 





The value of this research project lies in the fact that it was performed on mid-
trimester (14-19 gestational weeks) amniotic fluid samples obtained via trans-
abdominal amniocentesis from asymptomatic women. The size of the cohort, 
with a lost to follow-up rate (including missing data) of only 0.8% (10/1218), 
comprehensive databases with clinical variables, systematic processes and 
standardized methodology for sample collection and processing and the 
number of available aliquots, is unique. The major strengths are the well-
designed studies, using high-capacity techniques such as proteomics and 
metabolomics and multiplex approaches, which may be a key to increased 
understanding of spontaneous PTD, detection of novel biomarkers and to 
obtaining a complete picture of the process (172, 248).  Collection of samples 
at this gestational age is becoming increasingly rare due to the introduction of 
NIPT, and new cohorts like this are thus unlikely in future.   
The pathways underlying spontaneous PTD and the factors involved in the 
onset of labor were examined with a variety of different techniques involving 
both targeted and non-targeted approaches. This should be considered a 
strength, as it increases the chances of identifying normal and pathological 
processes.  
A major strength of this project is the high level of data accuracy. In all 
constituent studies, we collaborated with an experienced statistician and the 
statistical analyses were thus very thorough. Technical analyses were conduct-
ed in collaboration with research groups, rather than just using services to 
undertake the analyses, in order to extract maximal effects of the data and to 
be able to discuss findings. This had a major impact on our research.  
The database work and medical records reviews were undertaken meticulously 
by experienced midwives or medical students involved in research. The 
selection of groups was also meticulous and undertaken stepwise, in order to 
ensure data accuracy. Results of the exploratory proteomics studies were 
 
 
validated/replicated, which is otherwise frequently neglected. The fact that 
three proteins were disqualified from validation in Paper III should also be 
regarded as a sign of seriousness and accuracy, as a factor present within the 
amniotic fluid samples might have caused matrix interference. This might in 
turn have confounded interpretation of results causing bias.  
Another major strength is that this was a team-oriented multidisciplinary 
project in which the team members shared responsibility for the project but 
contributed different skills and responsibilities. These interdisciplinary 
collaborations led to optimized and efficient use of available resources. I have 
been involved in this long-term and extensive project since the very beginning 
and throughout all phases, including conception, acquiring funding, 
development, applications, planning and execution. This has led to substantial 
continuity, which must be regarded as a strength.  
 
6.9  Limitations 
 
The most important limitation is that women undergoing mid-trimester genetic 
amniocenteses constitute a highly selected population, as they are of a more 
advanced maternal age and have a higher risk of fetal chromosomal 
abnormalities than the overall population. This causes selection bias. Such 
mid-trimester amniotic fluid samples can, however, only be collected in 
line with clear clinical indications, such as genetic testing. By excluding 
women with known or suspected fetal abnormalities from the study and 
women with confirmed fetal abnormalities from analysis, bias was 
addressed to some extent.  
Of all the women who underwent a mid-trimester genetic amniocentesis during 
the study period, 24.2% were ineligible and 48.5% of  the eligible women were 
excluded. An important limitation is the lack of information about these 
women. In retrospect, it would have been preferable to ask all women 
presenting for mid-trimester genetic amniocentesis for permission to review 
their medical records. Questionnaires regarding dietary patterns and physical 
activity, collection of blood, saliva or urine samples (possibly reflecting the 
intrauterine environment as well as amniocentesis), or an ultrasound 
assessment of the cervix are other factors that might have complemented our 





was known to us at that stage. With current knowledge and experience, we 
might have been bolder and more innovative.  
A case-cohort design, with a control group limited to deliveries between 38+0 
and 41+6 gestational weeks and the use of matched cases and controls (as in 
the replication phase of Paper III as well as in Paper V), are not optimal for 
studying gestational duration. To maximize the chances of finding associations 
between protein concentrations and gestational duration, the latter should be 
treated as a continuous variable, as in Paper IV.  
The spontaneous PTD cases consisted of both PTL and PPROM cases, which 
can complicate detection of true differences. As DAMP expression is much 
more prone to be elevated in PPROM cases, a stratified analysis might have 
yielded other results.  
The risk of PTD in Sweden is generally low, 5.7% of all pregnancies, and 
approximately 3.5% are spontaneous. Despite the relatively large cohort of 
1218 women, the spontaneous PTD cases available for study are limited 
(n=51), making it difficult to draw conclusions. Studies of amniotic fluid from 
the general pregnant population at mid-trimester might have yielded other 
results, but this would have been neither feasible nor ethical. The studies may 
thus have been underpowered to detect smaller effect estimates of the 
biomarkers.  
 
6.10 The project’s future 
 
The research project is still in several different phases and this thesis does not 
mark its conclusion. Parts of the research have been presented at national and 
international congresses and meetings, attracting broad interest in the project 
and in the unique cohort of samples and associated medical data. As a first 
step, we will continue to investigate gestational duration in order to gain a 
deeper understanding of spontaneous PTD etiology. To gain greater 
understanding of the biological processes, integrating proteomics and 
metabolomics data into a multivariate model might be considered, as well as 
to further study the specific proteins that emerged in several of the papers. 
Further research is also needed to determine the effect of storage time and 
different processing conditions on protein concentrations.  
 
 
Even though spontaneous PTD is the focus of our research, the size of the 
cohort enables studies of a variety of pregnancy, delivery and neonatal 
outcomes, for which we have ethical approval to study. We have a substantial 
number of aliquots left in our biobanks and a comprehensive database with key 
research variables created especially for the overall project. Furthermore, we 
have organizational resources and well-organized and established collabora-
tions worldwide. Our ethical approvals permit the connection of data from the 
project to the extensive, comprehensive and world-renowned registers in 
Sweden. Together, these advantages enable future research, in which compo-
nents of mid-trimester amniotic fluid can be linked to other adverse pregnancy 
outcomes, such as preeclampsia.  
Due to the coordinated networks that most likely initiate the onset of delivery, 
inflammatory, immunological and other pathways have been examined in this 
thesis, as well as cellular metabolism. However, infections, dietary patterns, 
environmental factors and genetics probably interact with the inflammatory 
processes in ways as yet unknown to us. The published papers have high 
scientific value concerning both negative findings and potential biomarkers. 
We have now come to a point in our research where the right conditions exist 
for initiating studies of a more revolutionary character. This and other ongoing 
projects will now move on to an exciting and innovative level and we are 
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This thesis presents what should be considered as a snapshot of amniotic fluid 
composition in the mid-trimester with regard to the subsequent development 
of spontaneous PTD and the spontaneous onset of labor at term. The cohort 
represents a highly selected population with a low risk, from a global 
perspective, of spontaneous PTD. In accordance with the general rate, 
spontaneous PTDs in this cohort were mainly late cases, and the results should 
be interpreted accordingly. Alarmins and chemokines can assist in the 
determination of gestational duration in women with spontaneous onset of 
labor at term, and the inflammatory processes preceding the spontaneous onset 
of labor at term are present and detectable as early as in the mid-trimester. 
DAMPs are involved in natural biological processes such as remodeling of the 
tissues, and the concentrations measured at mid-trimester may be an indicator 
of functional fetal membranes and a functional placenta. 
The early prediction of spontaneous PTD remains a major challenge due to the 
complexity inherent in its diverse phenotypes, different underlying pathologies 
and a limited understanding of sequences and events preceding the condition. 
Potentially, spontaneous PTD may be the result of acute events not detectable 
in amniotic fluid as early as in the mid-trimester. Another possibility is that 
biological signals in early mid-trimester amniotic fluid may be of insufficient 
strength for accurate risk prediction of spontaneous PTD.  
A pregnancy clock, partly controlled by a timing mechanism linked to fetal 
development that regulates the onset of labor has previously been described in 
maternal blood/serum and in the placenta. The results presented this thesis and 
its constituent papers suggest that such a clock is also reflected in amniotic 
fluid, and that deviations from the clock may precede spontaneous PTD. 
Gestational age at sampling is strongly associated with the concentration of 
proteins in mid-trimester amniotic fluid. Not taking this into consideration in 
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8 Other research during the doctoral studies  
During this period, I have been involved in several other projects. Parallel 
studies of women with and without symptoms of threatening spontaneous 
PTD, and studies focusing on other pathways such as the infectious pathway 
(299) as well as being involved in follow-up studies of preterm-born neonates 
(300). Moreover, we have investigated the stability IL-6 (283), of one of the 
most promising biomarkers for spontaneous PTD prediction. Finally, I have 
contributed to several other projects, for which I have been acknowledged.  
 
8.1 Co-authored publications 
 
Stinson L*, Hallingström M*, Barman M, Viklund F, Keelan J, Kacerovsky 
M, Payne M, Jacobsson B. Comparison of bacterial DNA profiles in mid-
trimester amniotic fluid samples from preterm and term deliveries. 
Front Microbiol. 2020 Mar 24;11:415. 
 (* Equal contribution)  
This is the first paper from the cohort focusing on the infectious mechanisms 
of spontaneous PTD. The aim was to identify predictive bacterial DNA 
signatures in mid-trimester amniotic fluid. However, the samples proved to 
contain low-abundance and low-diversity bacterial DNA, and species 
typically associated with spontaneous PTD were absent. The majority of all 
samples were sterile but bacterial DNA was present in approximately one- 
fifth, suggesting that non-pathogenic bacteria may be present in amniotic 
fluid as early as in the mid-trimester.  
 
Thorell A, Hallingström M, Hagberg H, Fyhr I-M, Tsiartas P, Olsson I, 
Chaplin J E, Mallard C, Jacobsson B, Sävman K. Microbial invasion of the 
amniotic cavity is associated with impaired cognitive and motor function at 
school age in preterm children. Pediatric Research 2019 Nov 11. 
This study aimed to evaluate neurodevelopmental outcome, such as cognitive 
and motor function, in school-age children born at <34 gestational weeks 
and exposed to MIAC during gestation. Children exposed to MIAC had 
significantly lower scores for full-scale IQ, verbal IQ and motor function, 
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and addition of protease inhibitors on amniotic fluid interleukin-6 
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The aim of this study was to evaluate preanalytical handling procedures’ 
effect on IL-6 concentrations, measured by immunoassay. Amniotic fluid was 
collected from women undergoing elective cesarean section at gestational 
weeks 38+0 to 41+6. The influence of latency from sampling to 
centrifugation, centrifugal conditions (centrifugal force, time and 
temperature), supernate filtration and addition of protease inhibitors (serine, 
cysteine and metalloproteases) were compared to a standard group. ELISA 
was used for analysis within 8 months after sampling. IL-6 concentrations 
were not affected by the different preanalytical handling conditions.  
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